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ABSTRACT	  
Hereditary	  diffuse	  gastric	  cancer	  (HDGC)	  is	  an	  autosomal	  dominant	  
condition	  caused	  by	  a	  mutation	  in	  the	  tumour	  suppressor	  gene	  E-­‐cadherin,	  
(CDH1).	  It	  predisposes	  to	  a	  70%	  likelihood	  of	  developing	  highly	  penetrant	  
diffuse	  gastric	  cancer[1].	  Because	  HDGC	  is	  driven	  by	  the	  absence	  of	  a	  
tumour	  suppressor,	  conventional	  therapeutic	  approaches	  targeting	  
tumour-­‐promoting	  oncogenes	  cannot	  be	  used.	  	  Synthetic	  lethality	  is	  an	  
approach	  that	  circumvents	  this	  issue	  by	  targeting	  vulnerabilities	  in	  cells	  
that	  lack	  the	  functional	  tumour	  suppressor.	  This	  project	  aimed	  to	  
investigate	  a	  potential	  synthetic	  lethal	  relationship	  between	  CDH1	  and	  
polo-­‐like	  kinase	  3	  (PLK3),	  a	  cytoskeletal	  and	  cell	  cycle	  regulator.	  
Lentiviral	  delivery	  of	  two	  shRNA	  were	  successful	  in	  knocking	  down	  PLK3	  
expression	  in	  isogenic	  MCF10A	  cell	  lines,	  with	  and	  without	  CDH1	  
expression	  (MCF10A	  and	  CDH1-­‐/-­‐)	  [2].	  Viability	  was	  measured	  and	  
confirmed	  as	  synthetic	  lethal	  (mutations	  in	  combination	  cause	  cells	  to	  be	  
less	  viable)	  if	  the	  CDH1-­‐/-­‐	  cells	  were	  less	  viable	  with	  a	  ratio	  of	  ≤0.85.	  Results	  
from	  one	  shRNA	  knockdown	  trended	  towards	  synthetic	  lethality	  (p	  >	  0.05).	  
Another	  shRNA	  resulted	  with	  a	  considerable	  reverse	  synthetic	  lethal	  effect,	  
but	  was	  not	  statistically	  significant.	  
PLK	  antagonists	  poloxipan	  and	  wortmannin	  were	  used	  to	  inhibit	  PLK3	  [3].	  
Poloxipan	  induced	  reverse	  synthetic	  lethality	  with	  reduced	  viability	  in	  
MCF10A	  cells	  at	  low	  concentrations.	  High	  concentrations	  produced	  a	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marginal	  synthetic	  lethal	  phenotype.	  Wortmannin’s	  effect	  on	  MCF10A	  and	  
CDH1-­‐/-­‐	  cells	  also	  varied	  from	  synthetic	  lethal	  and	  reverse	  synthetic	  lethal.	  	  
As	  the	  viability	  of	  CDH1	  deficient	  cells	  could	  not	  be	  significantly	  reduced	  via	  
PLK3	  knockdown	  or	  inhibition,	  this	  candidate	  is	  no	  longer	  considered	  to	  be	  
a	  potential	  therapeutic	  target	  for	  the	  treatment	  of	  HDGC.	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1  INTRODUCTION	  
1.1 HEREDITARY	  DIFFUSE	  GASTRIC	  CANCER	  
In	  this	  thesis	  a	  potential	  synthetic	  lethal	  partner	  of	  E-­‐cadherin	  (CDH1)	  and	  
cytoskeletal	  regulator,	  polo-­‐like	  kinase	  3	  (PLK3)	  is	  targeted	  in	  CDH1	  
deficient	  cells	  to	  aid	  in	  the	  investigation	  for	  a	  novel	  treatment	  for	  
Hereditary	  diffuse	  gastric	  cancer	  (HDGC).	  HDGC	  was	  first	  coined	  after	  it	  
was	  identified	  in	  three	  New	  Zealand	  Maori	  families	  with	  an	  autosomal	  
dominant	  inheritance	  of	  diffuse	  gastric	  cancer	  [4].	  HDGC	  is	  caused	  by	  a	  
germ	  line	  genetic	  mutation	  in	  the	  E-­‐cadherin	  gene	  (CDH1).	  Having	  a	  CDH1	  
mutation	  leaves	  carriers	  with	  a	  70%	  likelihood	  of	  developing	  diffuse	  gastric	  
cancer	  and	  a	  40%	  likelihood	  of	  developing	  lobular	  breast	  cancer	  [1,5].	  	  
Current	  clinical	  procedure	  for	  those	  who	  have	  a	  CDH1	  mutation	  is	  to	  
conduct	  a	  total	  prophylactic	  gastrectomy.	  Removing	  their	  stomach	  has	  a	  
highly	  adverse	  impact	  on	  the	  patient’s	  quality	  of	  life	  and	  alternative	  
treatments	  are	  needed[6].	  PLK3	  has	  been	  identified	  as	  a	  therapeutic	  target	  
in	  a	  high	  throughput	  small	  interfering	  RNA	  (siRNA)	  screen	  and	  needs	  to	  be	  
investigated	  as	  to	  whether	  it	  can	  cause	  synthetic	  lethality	  in	  cases	  of	  HDGC.	  	  
1.1.1 IDENTIFICATION	  	  
HDGC	  was	  first	  identified	  in	  a	  New	  Zealand	  Maori	  family	  with	  heritable	  
early	  onset	  gastric	  cancer.	  In	  1964,	  a	  21-­‐year-­‐old	  male	  came	  to	  hospital	  
with	  inoperable	  carcinoma	  of	  the	  stomach.	  His	  cousin	  had	  died	  the	  year	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before	  with	  the	  same	  condition.	  Tracing	  their	  family	  history	  back	  to	  the	  
1850s	  (Figure	  1),	  cases	  of	  early	  onset	  gastric	  cancer	  were	  observed	  over	  
three	  generations,	  with	  many	  dying	  at	  a	  young	  age	  [7].	  	  
	  
Figure	   1	   -­‐	  Family	   pedigree	   showing	  HDGC .	  Cases	  of	  gastric	  cancer	   labelled	  Ca.	  
stomach	  7.	  
In	  1998,	  a	  genetic	  linkage	  analysis	  was	  conducted	  on	  the	  same	  family.	  This	  
allowed	  the	  tracking	  of	  their	  mutation	  to	  a	  genetic	  interval	  on	  chromosome	  
16q22.1	  and	  the	  CDH1	  gene.	  Subsequent	  single	  stranded	  conformational	  
polymorphism	  (SSCP)	  mutation	  analysis	  identified	  a	  band	  shift	  in	  exon	  7	  of	  
the	  CDH1	  gene	  that	  was	  found	  in	  cases	  of	  diffuse	  gastric	  cancer	  from	  this	  
family	  but	  was	  absent	  in	  150	  other	  unrelated	  chromosomes	  (1008G>T).	  
This	  change	  affects	  one	  of	  the	  E-­‐cadherin	  calcium	  binding	  pockets	  required	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for	  the	  dimerization	  and	  the	  formation	  of	  rigid	  cell-­‐to-­‐cell	  adhesions	  and	  
reduces	  splicing	  efficiency.	  This	  and	  other	  subsequently	  identified	  genetic	  
alterations	  on	  CDH1	  render	  E-­‐cadherin	  dysfunctional	  and	  prompted	  further	  
research	  into	  HDGC	  and	  how	  it	  can	  be	  treated.	  	  
1.1.2 INCREASING	  AWARENESS	  OF	  HDGC	  
Gastric	  cancer	  is	  the	  third	  leading	  cause	  of	  cancer	  death	  worldwide	  with	  
70-­‐85%	  of	  the	  1	  million	  individuals	  affected	  dying	  within	  5	  years	  of	  
diagnosis.	  Lack	  of	  treatment	  options	  and	  late	  diagnosis	  contribute	  to	  this	  
statistic,	  however	  further	  progress	  has	  been	  made	  in	  identifying	  HDGC	  
cases	  because	  of	  increased	  genetic	  screening	  and	  identifying	  [8].	  CDH1	  was	  
identified	  as	  a	  cause	  of	  HDGC	  in	  1998,	  resulting	  in	  additional	  families	  
worldwide	  testing	  positive	  for	  CDH1	  mutations.	  There	  are	  now	  reports	  on	  
over	  104	  unique	  CDH1	  mutations	  in	  cases	  of	  HDGC	  across	  many	  various	  
ethnic	  origins	  (Table	  1)	  [8].	  	  
Table	   1	   -­‐	   Pathogenic	   germline	   defects	   in	   HDGC.	   Type,	   frequency	   and	  
recurrence	  of	  CDH1	  and	  CTNNA1	  mutations	  8	  
Mutation	  Type	   Frequency	   Recurrence	  
CDH1	  
Frameshift	   39/104	  (38%)	   10/39	  (26%)	  
Splice	  Site	   24/104	  (23%)	   10/24	  (42%)	  
Missense	   18/104	  (17%)	   7/18	  (39%)	  
Nonsense	   18/104	  (17%)	   7/18	  (39%)	  
Large	  Rearrangements	   9/104	  (9%)	   4/9	  (44%)	  
CTNNA1	  
Frameshift	   1/1	   NA	  
	  
Identification	  of	  CDH1	  mutations	  in	  multiple	  families	  aided	  with	  
understanding	  of	  HDGC	  and	  tumour	  development.	  Onset	  of	  HDGC	  begins	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after	  a	  second	  hit	  on	  the	  CDH1	  gene	  abrogates	  all	  E-­‐cadherin	  expression	  
[9,10].	  In	  accordance	  with	  the	  Knudson	  hypothesis,	  the	  first	  hit	  is	  the	  
inheritance	  of	  a	  mutated	  CDH1	  allele,	  whilst	  still	  having	  a	  functional	  copy	  of	  
CDH1	  in	  the	  other	  allele	  [11].	  Hyper-­‐methylation	  of	  the	  CDH1	  promoter	  
region	  silences	  the	  second	  CDH1	  allele	  in	  over	  50%	  of	  cases	  of	  HDGC.	  This	  
silencing	  is	  the	  second	  hit,	  leaving	  the	  carrier	  with	  a	  total	  loss	  of	  E-­‐
cadherin.	  Some	  report	  as	  high	  as	  83%	  of	  diffuse	  gastric	  cancer	  cases	  have	  
hyper-­‐methylation	  of	  the	  CDH1	  promoter	  and	  can	  occur	  regardless	  of	  
whether	  CDH1	  itself	  is	  mutated	  or	  not	  [10,12,13].	  	  
As	  shown	  by	  the	  failure	  to	  identify	  CDH1	  mutations	  in	  some	  HDGC	  families,	  
not	  all	  familial	  gastric	  cancer	  cases	  are	  explained	  by	  CDH1	  mutations	  and	  
CDH1	  methylated	  silencing	  [5,14-­‐17].	  The	  CTNNA1	  gene	  that	  codes	  for	  α-­‐
catenin	  was	  identified	  in	  2013	  in	  one	  HDGC	  family	  (Table	  1)	  [18].	  α-­‐Catenin	  
is	  part	  of	  the	  cytoskeleton	  structure	  that	  binds	  to	  E-­‐cadherin	  forming	  stable	  
adherens	  junctions.	  This	  identification	  is	  further	  evidence	  of	  the	  important	  
association	  between	  the	  cytoskeletal	  structures	  and	  the	  adherens	  junction.	  
Having	  a	  biologically	  plausible	  target	  that	  is	  vulnerability	  for	  the	  
development	  of	  novel	  synthetic	  lethal	  therapeutic	  treatments	  such	  as	  
targeting	  PLK3	  [15].	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1.1.3 MANAGEMENT	  OF	  HDGC	  
After	  identifying	  CDH1	  mutations	  in	  HDGC,	  a	  protocol	  was	  created	  by	  the	  
International	  Gastric	  Cancer	  Linkage	  Consortium	  for	  the	  guidance	  of	  
medical	  professionals	  working	  with	  HDGC	  [19,20].	  A	  clinical	  and	  
psychosocial	  benefit	  results	  from	  family	  members	  knowing	  if	  they	  have	  
inherited	  the	  defective	  CDH1	  gene	  because	  carriers	  have	  a	  70%	  likelihood	  
of	  developing	  an	  aggressive	  diffuse	  gastric	  cancer	  [1,19].	  Biopsies	  are	  the	  
current	  gold	  standard	  of	  pathological	  diagnosis.	  The	  major	  distinguishing	  
pathological	  features	  of	  diffuse	  gastric	  cancer	  are	  the	  signet-­‐ring	  cell	  
carcinomas,	  evident	  in	  H&E	  staining	  as	  cells	  with	  a	  large	  vacuole	  that	  
contains	  the	  glycosylated	  mucin	  proteins	  (Figure	  2)	  [21].	  Signet-­‐ring	  cell	  
carcinomas	  in	  the	  biopsy	  are	  a	  key	  indicator	  that	  strongly	  indicates	  
gastrectomy	  as	  treatment	  [22].	  	  
	  
Figure	   2	   -­‐	   Stage	   T1a	   signet	   ring	   cell	   carcinoma	   from	   a	   CDH1	   germline	  
mutation	   carrier.	   The	   9-­‐mm	   focus	   (occupying	   the	   left	   two-­‐thirds	   of	   the	   frame)	  
occupies	   the	   full	   thickness	  of	   the	  mucosa	  under	  an	   intact	  epithelium	  (H&E,	  ×40).	  
The	  inset	  frame	  shows	  signet	  ring	  cells	  in	  the	  lamina	  propria	  at	  ×400	  [22].	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When	  a	  patient	  has	  tested	  positive	  for	  a	  germline	  CDH1	  mutation,	  carriers	  
are	  then	  presented	  with	  the	  only	  guaranteed	  preventative	  of	  diffuse	  gastric	  
cancer,	  a	  total	  prophylactic	  gastrectomy.	  The	  alternative	  is	  to	  continue	  to	  
be	  monitored	  by	  biopsies.	  [13,19,20,23].	  The	  carrier	  then	  holds	  in	  
consideration	  the	  prevalence	  of	  developing	  diffuse	  gastric	  cancer	  with	  a	  
likelihood	  of	  70%	  or	  a	  new	  life	  without	  a	  stomach.	  The	  operation	  itself	  has	  
a	  mortality	  rate	  of	  1-­‐2%,	  leads	  to	  morbidity,	  dramatic	  weight	  loss,	  and	  
restrictive	  diets	  that	  impact	  their	  quality	  of	  life.	  Patients	  also	  infrequently	  
suffer	  from	  oesophagitis	  and	  women	  with	  the	  mutation	  will	  still	  have	  the	  
increased	  risk	  of	  developing	  lobular	  breast	  cancer	  [6,24].	  Prophylactic	  
gastrectomy	  prevents	  diffuse	  gastric	  cancer	  but	  the	  high	  cost	  of	  this	  
procedure	  makes	  investigation	  into	  alternative	  measures	  essential.	  	  
1.2 E-­‐CADHERIN	  AND	  POLO-­‐LIKE	  KINASE	  3	  
E-­‐cadherin	  (CDH1)	  is	  a	  calcium-­‐dependent	  cell-­‐cell	  adhesion	  protein	  of	  the	  
adherens	  junction.	  E-­‐cadherin	  maintains	  cell	  polarity,	  connects	  to	  the	  
cytoskeleton	  and	  is	  a	  regulator	  of	  cell	  signalling.	  E-­‐cadherin	  was	  the	  first	  of	  
the	  cadherin	  family	  to	  be	  discovered	  so	  that	  there	  is	  a	  comprehensive	  but	  
incomplete	  understanding	  of	  its	  role	  in	  the	  cell	  [25].	  Further	  research	  will	  
be	  beneficial	  to	  understanding	  E-­‐cadherin’s	  role	  as	  a	  tumour	  suppressor	  
and	  driver	  of	  diffuse	  gastric	  cancer	  and	  lobular	  breast	  cancer	  [26].	  	  
In	  a	  siRNA	  screen,	  conducted	  by	  our	  laboratory	  polo-­‐like	  kinase	  3	  (PLK3)	  
was	  found	  to	  be	  in	  a	  synthetic	  lethal	  relationship	  with	  CDH1	  (Table	  2,	  
Figure	  3)	  [27].	  The	  synthetic	  lethal	  treatment	  concept	  is	  applicable	  in	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tumour	  suppressor	  cases	  such	  as	  HDGC.	  A	  synthetic	  lethal	  partner	  of	  CDH1	  
such	  as	  PLK3	  can	  then	  be	  targeted	  to	  cause	  cell	  death	  only	  in	  CDH1	  mutant	  
tumour	  cells.	  If	  the	  two	  genes	  are	  in	  a	  synthetic	  lethal	  partnership,	  the	  
mutated	  CDH1	  cancer	  cells	  will	  die,	  while	  the	  non-­‐mutated	  CDH1	  cells	  
remain	  viable.	  	  
Table	   2	   -­‐	   Viability	   of	   MCF10A	   and	   CDH1-­‐/-­‐	   cells	   from	   the	   siRNA	   screen.	  
Measured	   24	   hours	   (hrs)	   after	   treatment	   for	   luminescence	   value	   to	   reflect	   the	  
amount	   of	   viable	   cells.	   The	   treatments	   were	   normalised	   to	   a	   mock	   siRNA	   and	  
compared	   for	   a	   viability	   ratio.	   The	   threshold	   to	   be	   considered	   a	   synthetic	   lethal	  
relationship	   was	   a	   viability	   ratio	   of	   ≥0.85	   and	   was	   seen	   in	   the	   original	   pool	   of	  
siRNA,	  siRNA2	  and	  siRNA4.	  
Viabilty	  from	  siRNA	  Screen	  
	   MCF10A	   CDH1
-­‐/-­‐	   Viability	  Ratio	  
siRNA1	   0.92	   0.82	   0.89	  
siRNA2	   0.68	   0.52	   0.76	  
siRNA3	   0.62	   0.68	   1.10	  
siRNA4	   0.66	   0.52	   0.79	  
Pool	  of	  siRNA	   0.90	   0.76	   0.84	  
	  
	  
Figure	   3	   -­‐	   Viability	   of	   the	   MCF10A	   and	   CDH1-­‐/-­‐	   cells	   from	   the	   high	  
throughput	   screen	   of	   siRNA	   Cells	   were	   treated	   with	   four	   individual	   siRNA	  
sequences	   that	   targeted	   the	   knockdown	   PLK3	   mRNA.	   After	   24	   hrs	   the	  
luminescence	   determined	   the	   amount	   of	   cells	   and	   the	   siRNA	   value	   was	  
normalised	   to	   the	   average	   of	   the	   siRNA	   mock	   control.	   The	   threshold	   to	   be	  
considered	   a	   synthetic	   lethal	   relationship	  was	   a	   viability	   ratio	   of	   ≥0.85	   and	  was	  

























	   21	  
PLK3	  is	  a	  serine/threonine-­‐protein	  kinase	  that	  serves	  as	  a	  cyto-­‐skeletal	  
regulator	  and	  cell	  cycle	  regulator.	  Specifically,	  PLK3	  interacts	  with	  the	  
spindle	  poles	  during	  mitosis.	  It	  also	  functions	  as	  a	  tumour	  suppressor	  
causing	  cell	  cycle	  arrest	  in	  response	  to	  a	  variety	  of	  stress	  conditions	  such	  as	  
genetic	  damage	  or	  hypoxia	  [28].	  It	  is	  of	  great	  interest	  to	  validate	  whether	  a	  
CDH1	  mutation	  and	  the	  knock	  down	  of	  PLK3	  will	  induce	  the	  synthetic	  lethal	  
effect,	  because	  of	  the	  tumour	  suppressor	  properties	  of	  PLK3.	  
1.2.1 DISCOVERY	  AND	  ROLE	  OF	  E-­‐CADHERIN	  
The	  first	  report	  of	  E-­‐cadherin	  came	  after	  discovery	  that	  Ca2+	  in	  the	  
presence	  of	  a	  150kDa	  sized	  surface	  protein	  was	  able	  to	  protect	  cells	  from	  
trypsinization	  by	  maintaining	  increased	  adhesion	  [29].	  E-­‐cadherin	  was	  first	  
named	  uvomorulin	  after	  anti-­‐uvomorulin	  antibodies	  impaired	  a	  mouse	  
morula,	  rendering	  the	  structure	  to	  resemble	  uva	  (Latin	  for	  grapes)	  [30].	  	  
Eventually	  a	  discrepancy	  was	  identified	  in	  the	  effects	  of	  antibodies	  that	  
inhibited	  adhesion	  on	  a	  68kDa	  protein	  in	  liver	  cells,	  but	  were	  not	  able	  to	  
cause	  similar	  inhibition	  of	  adhesion	  in	  retinal	  cells.	  Another	  antibody	  that	  
inhibited	  epithelial	  cell	  adhesion	  was	  ineffective	  against	  adhesion	  of	  
fibroblastic	  cells.	  New	  antibodies	  were	  developed	  that	  were	  able	  to	  
specifically	  inhibit	  the	  cell-­‐cell	  adhesion	  in	  the	  fibroblasts	  and	  for	  other	  
tissues	  and	  these	  proteins	  became	  known	  as	  “cadherins”	  after	  their	  tissue	  
type	  (E	  for	  epithelial	  cadherin)	  [31,32].	  	  
E-­‐cadherin,	  as	  a	  member	  of	  the	  cadherin	  superfamily,	  is	  a	  calcium	  
dependent	  cell-­‐cell	  adhesion	  glycoprotein	  coded	  for	  at	  position	  q22.1	  on	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chromosome	  16	  of	  homo	  sapiens	  [25].	  It	  has	  a	  cytoplasmic	  domain,	  a	  
transmembrane	  domain,	  and	  an	  external	  E-­‐cadherin	  domain.	  The	  external	  
E-­‐cadherin	  domain	  consists	  of	  five	  repeat	  domains,	  the	  fifth	  domain	  being	  
distinguishable	  by	  four	  cysteines.	  This	  fifth	  domain	  is	  reduced	  to	  form	  
strong	  disulphide	  bridges	  with	  a	  neighbouring	  cell’s	  fifth	  extracellular	  
domain,	  forming	  cell-­‐cell	  adhesion.	  The	  cytoplasmic	  domain	  has	  become	  a	  
great	  point	  of	  interest	  in	  research	  recently	  because	  of	  its	  involvement	  in	  
many	  other	  pathways,	  such	  as	  involving	  the	  WNT	  pathway,	  Rho	  GTPase	  ,	  
multiple	  catenins,	  myosins,	  F-­‐actin	  and	  various	  other	  cell	  skeleton	  
constituents	  (Figure	  4)	  [33-­‐35].	  Contributing	  to	  these	  pathways	  E-­‐cadherin	  
loss/mutation	  has	  the	  potential	  to	  affect	  a	  range	  of	  processes	  ultimately	  
leading	  to	  HDGC.	  
	  
Figure	   4	   –	   E-­‐cadherin	   function.	   The	   junction	   between	   two	   neighbouring	  
epithelial	   cells	   and	   the	   various	   integrations	   of	   cytoskeletal	   structures	   and	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1.2.2 TREATING	  E-­‐CADHERIN	  DEFICIENT	  CELLS	  
E-­‐cadherin	  is	  a	  tumour	  suppressor	  lost	  in	  the	  early	  stages	  of	  gastric	  and	  
breast	  cancer	  and	  an	  invasion	  suppressor	  lost	  in	  the	  late	  stages	  of	  various	  
other	  cancer	  types.	  Cancer	  inducing	  somatic	  CDH1	  mutations	  were	  
identified	  in	  diffuse	  gastric	  cancer	  before	  the	  discovery	  of	  germline	  CDH1	  
mutations	  [37].	  These	  sporadic	  cases	  had	  a	  truncated	  E-­‐cadherin	  due	  to	  
somatic	  mutations	  causing	  exon	  skipping.	  Additionally,	  other	  tissue	  types	  
may	  down-­‐regulate	  or	  have	  mutant	  CDH1	  allowing	  for	  late	  invasive	  abilities	  
in	  bladder,	  colon,	  lung,	  oesophagus,	  ovary	  and	  thyroid	  carcinomas	  but	  
germline	  mutations	  of	  CDH1	  in	  these	  cancers	  are	  very	  rare	  [25,38].	  E-­‐
cadherin	  loss	  initiates	  gastric	  and	  breast	  cancer	  formation	  by	  loss	  of	  the	  
cell’s	  polarity	  and	  adhesion	  (Figure	  2).	  It	  is	  important	  to	  target	  the	  
vulnerabilities	  this	  loss	  provides	  before	  the	  diffuse	  gastric	  cancer	  tumour	  
advances.	  
When	  a	  tumour	  suppressor	  such	  as	  CDH1	  becomes	  mutated	  and	  does	  not	  
function	  normally,	  it	  leads	  to	  the	  formation	  of	  a	  tumour.	  Directly	  targeting	  
the	  mutated	  tumour	  suppressor	  is	  not	  possible,	  because	  unlike	  a	  cancer	  
causing	  oncogenic	  protein,	  it	  is	  the	  absence	  of	  the	  tumour	  suppressor	  gene	  
that	  causes	  cancer	  in	  this	  case.	  An	  example	  of	  targeting	  an	  oncogene	  is	  the	  
overactive	  oestrogen	  receptor	  in	  breast	  cancer.	  This	  oncogene	  promotes	  
the	  cancer	  growth	  and	  is	  targetable	  with	  a	  treatment	  of	  and	  inhibitor,	  anti-­‐
oestrogen	  drug	  tamoxifen	  [39].	  For	  cases	  with	  CDH1	  tumour	  suppressor	  
loss,	  it	  is	  not	  possible	  to	  target	  the	  cause,	  as	  the	  protein	  is	  already	  lost.	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Therefore	  another	  treatment	  target	  other	  than	  the	  causal	  mutation	  (CDH1)	  
is	  needed.	  
One	  such	  treatment	  strategy	  is	  termed	  synthetic	  lethality;	  a	  proven	  concept	  
where	  a	  second	  allelic	  trait	  is	  considered	  a	  synthetic	  lethal	  partner	  of	  the	  
first	  trait	  (CDH1).	  The	  two	  traits	  are	  compatible	  with	  life	  separately,	  but	  a	  
combination	  of	  loss	  of	  both	  traits	  is	  lethal	  (Figure	  5).	  The	  synthetic	  lethal	  
technique	  is	  used	  in	  cancer	  treatments	  when	  tumour	  targets	  are	  absent	  
(such	  as	  CDH1)	  due	  to	  the	  mutation	  inactivating	  a	  tumour	  suppressor	  gene.	  
This	  loss	  becomes	  the	  first	  trait	  that	  will	  make	  it	  vulnerable	  to	  the	  targeting	  
of	  its	  synthetic	  lethal	  partner	  [40].	  	  
	  
Figure	   5	   -­‐	   Synthetic	   lethality.	   Two	   genes	   are	   synthetic	   lethal	   only	   when	   their	  
simultaneous	   inactivation	   results	   in	   cellular	   or	   organismal	   death.	   In	   this	  
example,	   deletion	   of	   either	   gene	   A	   or	   gene	   B	   does	   not	   affect	   viability	   whereas	  
inactivation	  of	  both	  at	  the	  same	  time	  is	  lethal	  [40].	  	  
A	  great	  example	  of	  where	  this	  technique	  is	  currently	  in	  clinical	  use	  is	  with	  
BRCA	  mutations	  and	  poly	  ADP-­‐ribose	  polymerase	  (PARP)	  inhibitors.	  PARP	  
inhibitors	  provide	  a	  synthetic	  lethal	  hit	  to	  BRCA	  mutated	  cells	  [41].	  Tumour	  
suppressors	  BRCA1	  and	  BRCA2	  are	  DNA	  repair	  proteins.	  DNA	  damage	  
would	  accumulate	  without	  functioning	  BRCA	  proteins,	  and	  cells	  with	  this	  
mutation	  are	  prone	  to	  further	  oncogenic	  mutations	  allowing	  for	  tumour	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growth	  [42].	  PARPs	  are	  also	  involved	  in	  repair	  of	  DNA,	  repairing	  single-­‐
stranded	  breaks.	  It	  was	  found	  that	  PARP	  inhibition	  has	  a	  lethal	  effect	  in	  
cells	  with	  BRCA	  mutations	  but	  does	  not	  cause	  any	  significant	  loss	  in	  WT	  
cells	  that	  have	  functioning	  BRCA	  [43].	  Synthetic	  lethality	  caused	  by	  PARP	  
inhibitors	  continues	  to	  be	  a	  successful	  treatment	  strategy,	  inspiring	  
multiple	  other	  efforts	  to	  find	  targeted	  synthetic	  lethal	  combinations	  for	  
other	  tumour	  suppressor	  mutations	  such	  as	  with	  CDH1.	  
A	  high	  throughput	  screen	  conduced	  in	  our	  laboratory	  using	  a	  siRNA	  library	  
on	  a	  MCF10A	  breast	  cancer	  cell	  line	  and	  its	  isogenic	  partner	  (MCF10A	  with	  
a	  CDH1-­‐/-­‐	  deletion	  referred	  to	  hereafter	  as	  CDH1-­‐/-­‐)	  identified	  various	  
synthetically	  lethal	  candidates	  [2,27].	  Each	  pool	  of	  four	  siRNAs	  would	  
specifically	  targeted	  the	  knockdown	  of	  one	  out	  of	  18,120	  genes	  in	  MCF10A	  
and	  CDH1-­‐/-­‐	  cells.	  A	  gene	  was	  considered	  to	  be	  a	  synthetically	  lethal	  partner	  
of	  CDH1	  if	  the	  ratio	  of	  CDH1-­‐/-­‐	  cell	  viability	  over	  MCF10A	  viability	  was	  
≤0.85.	  PLK3	  was	  one	  of	  the	  candidates	  making	  these	  thresholds.	  The	  
viability	  of	  the	  MCF10A	  cells	  was	  0.90	  after	  the	  PLK3	  knockdown	  and	  the	  
viability	  of	  the	  CDH1-­‐/-­‐	  cells	  was	  0.76.	  This	  provided	  a	  viability	  ratio	  of	  0.84.	  
In	  the	  secondary	  screen,	  PLK3	  was	  amongst	  500	  gene	  candidates	  that	  had	  
the	  shRNA	  pool	  de-­‐convoluted	  to	  test	  the	  four-­‐pooled	  siRNAs	  individually.	  
Of	  the	  four	  siRNAs	  targeting	  PLK3,	  2	  out	  of	  4	  were	  above	  the	  standards	  to	  
be	  considered	  synthetically	  lethal.	  Another	  factor	  that	  promotes	  PLK3	  as	  a	  
synthetic	  lethal	  partner	  of	  CDH1	  is	  PLK3’s	  biological	  relevance	  as	  a	  tumour	  
suppressor	  and	  its	  interactions	  with	  E-­‐cadherin.	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1.2.3 POLO-­‐LIKE	  KINASE	  3	  
Polo-­‐like	  kinases	  are	  a	  family	  of	  kinases	  that	  regulate	  the	  cell	  cycle.	  They	  all	  
have	  an	  amino-­‐terminal	  serine/threonine	  kinase	  catalytic	  domain	  and	  
distinguishing	  polo	  box	  domains	  [44].	  Polo-­‐like	  kinase	  1	  (PLK1)	  is	  a	  
research	  validated	  therapeutic	  cancer	  target	  that	  induces	  cell	  death.	  PLK3	  
however	  is	  not	  as	  well	  understood	  [45,46].	  The	  similarity	  of	  all	  the	  PLKs	  
allows	  them	  to	  be	  targeted	  by	  similar	  inhibitors	  with	  varying	  and	  currently	  
undetermined	  quantification.	  This	  casts	  a	  shadow	  on	  this	  therapeutic	  
research,	  as	  PLK1	  inhibitors	  are	  not	  specific	  to	  PLK1	  and	  some	  of	  the	  anti-­‐
cancer	  therapeutic	  effects	  could	  be	  attributed	  to	  the	  inhibition	  of	  other	  
PLKs	  [47].	  PLK	  inhibitors	  are	  currently	  undergoing	  clinical	  trials,	  despite	  
their	  off	  target	  inhibition	  not	  yet	  being	  well	  characterised.	  This	  is	  not	  
unusual	  for	  drug	  therapies.	  	  
The	  subtle	  difference	  in	  each	  PLK	  gives	  these	  kinases	  a	  unique	  functional	  
role.	  Upon	  DNA	  damage,	  ataxia	  telangiectasia	  mutated	  (ATM)	  indirectly	  
causes	  phosphorylation	  of	  PLK3.	  This	  relationship	  is	  not	  a	  directly	  
phosphorylation	  but	  PLK3	  is	  dependent	  on	  ATM’s	  presence	  [48].	  PLK3	  will	  
however	  directly	  phosphorylate	  p53,	  allowing	  for	  activation	  of	  cell	  cycle	  
arrest	  and	  apoptosis	  if	  the	  signal	  is	  sustained	  in	  situations	  of	  excessive	  DNA	  
damage.	  PLK3	  activates	  cell	  cycle	  arrest	  via	  activation	  of	  CHK2	  that	  will	  
then	  acts	  at	  the	  G2/M	  transition,	  and	  inhibits	  CDC25,	  an	  activator	  of	  cell	  
cycle	  progression	  (Figure	  6)	  [48-­‐51].	  Despite	  the	  lack	  of	  a	  complete	  
association	  at	  every	  step,	  the	  evidence	  that	  implicates	  PLK3	  as	  a	  tumour	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suppressor	  is	  strong.	  The	  gaps	  in	  our	  knowledge	  regarding	  the	  associations	  
of	  PLK3	  make	  it	  difficult	  to	  predict	  the	  effects	  of	  targeting	  this	  kinase.	  	  
	  
Figure	   6	   -­‐	   Known	   tumour	   suppressor	   functions	   of	   PLK3.	   PLK3	   regulates	   a	  
number	  of	   cellular	  activities	  by	  modulating	  a	  wide	  array	  of	   cellular	   components.	  
Arrows	  indicate	  activation	  and	  T-­‐bars	  indicate	  inhibition.	  
PLK3	  shows	  other	  tumour	  suppressor	  qualities	  such	  as	  activating	  DNA	  
repair	  and	  inhibiting	  angiogenesis	  (Figure	  6).	  It	  is	  proven	  to	  associate	  with	  
and	  cause	  phosphorylation	  of	  DNA	  repair	  polymerase	  δ,	  in	  combination	  
with	  previously	  mentioned	  cell	  cycle	  arrest.	  This	  allows	  DNA	  repair	  to	  
occur,	  resulting	  in	  fewer	  mutations	  accumulating	  with	  each	  cell	  division	  
[49].	  Expression	  of	  hypoxia-­‐inducible	  factor	  1-­‐alpha	  (HIF-­‐1α)	  is	  often	  
increased	  in	  tumours	  as	  the	  growth	  of	  a	  tumour	  renders	  a	  state	  of	  hypoxia	  
due	  to	  the	  lack	  of	  blood	  supply.	  HIF-­‐1α	  initiates	  angiogenesis	  so	  that	  
oxygenated	  blood	  can	  be	  delivered	  to	  the	  oxygen	  deprived	  tumour	  cells,	  
allowing	  for	  further	  tumour	  growth.	  PLK3	  acts	  as	  a	  tumour	  suppressor	  by	  
directly	  phosphorylating	  HIF-­‐1α,	  causing	  it	  to	  be	  destabilized	  and	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repressed	  [52].	  PLK3	  also	  phosphorylates	  and	  stabilises	  PTEN,	  which	  then	  
inhibits	  HIF-­‐1α	  [28,52,53].	  	  
However,	  these	  tumour	  suppressor	  characteristics	  are	  not	  associated	  with	  
E-­‐cadherin.	  PLK3	  is	  relevant	  to	  E-­‐cadherin	  in	  that	  it	  is	  a	  regulator	  of	  the	  cell	  
cytoskeletal	  network.	  Inactivation	  of	  PLK3	  causes	  disruption	  of	  the	  
cytoskeletal	  structures	  and	  can	  lead	  to	  apoptosis.	  PLK3	  has	  been	  identified	  
accumulating	  around	  centrioles	  and	  the	  cells	  spindle	  poles	  during	  
metaphase	  by	  immunofluorescence	  imaging	  of	  cells	  during	  mitosis.	  During	  
telophase,	  PLK3	  accumulates	  by	  the	  mid-­‐body	  where	  cytokinesis	  is	  
occurring	  [54].	  PLK3	  over-­‐expression	  causes	  a	  shrunken	  conformation	  of	  
cells	  with	  a	  more	  rounded	  morphology.	  	  
Knockdown	  of	  PLK3	  by	  RNA	  inhibition	  with	  short	  hairpin	  RNA	  (shRNA)	  
and	  a	  non-­‐functional	  PLK3	  mutant	  causes	  microtubule	  structures	  to	  be	  
elongated	  and	  protrude	  through	  cell	  walls	  with	  an	  increase	  of	  apoptosis	  
[54-­‐56].	  Other	  findings	  confirm	  this	  pattern,	  with	  activated	  PLK3	  forming	  
complexes	  with	  un-­‐polymerized	  tubulin,	  promoting	  its	  formation.	  PLK3	  
inhibition	  causes	  incomplete	  cytokinesis,	  multinucleated	  division,	  Golgi	  
fragmentation	  causing	  “mitotic	  catastrophe”	  and	  apoptosis	  (Figure	  7)	  
[47,48,51,55,57].	  It	  is	  expected	  that	  the	  increased	  lethality	  observed	  in	  
CDH1-­‐/-­‐	  cells	  is	  due	  to	  an	  increased	  vulnerability	  to	  cytoskeletal	  structures	  
penetrating	  the	  cell	  membrane	  and	  causing	  mitotic	  catastrophe.	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Figure	   7	   -­‐	   T47D	   cells	   with	   PLK3	   knockdown	   by	   shRNA.	   Knockdown	   causes	  
apoptosis	  and	  multinucleated	  cells	  compared	  to	  the	  plasmid	  vector	  [57].	  
Yet	  to	  be	  identified	  is	  any	  direct	  interaction	  between	  PLK3	  and	  E-­‐cadherin	  
that	  gives	  biological	  plausibility	  to	  the	  hypothesis	  that	  CDH1-­‐/-­‐	  cells	  will	  be	  
synthetically	  lethal	  with	  PLK3	  knockdown	  or	  inhibition.	  
1.3 EXPERIMENTAL	  AIM	  	  
The	  aim	  of	  this	  project	  is	  to	  validate	  any	  synthetic	  lethality	  when	  PLK3	  is	  
targeted	  in	  MCF10A	  cells.	  PLK3	  expression	  will	  be	  knocked	  down	  using	  
shRNA	  (an	  alternative	  to	  the	  siRNA	  used	  in	  the	  high	  throughput	  screen).	  
PLK3	  will	  also	  be	  inhibited	  using	  current	  non-­‐specific	  PLK	  inhibitors	  
poloxipan	  and	  wortmannin	  targeting	  PLK	  proteins	  in	  MCF10A	  and	  CDH1-­‐/-­‐	  
cells.	  The	  outcomes	  of	  this	  study	  will	  impact	  further	  research	  efforts	  in	  
finding	  a	  treatment	  to	  prevent	  HDGC	  and	  provide	  further	  insights	  on	  the	  
effects	  of	  PLK	  inhibition.	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1.4 EXPERIMENTAL	  BACKGROUND	  
1.4.1 LENTIVIRAL	  SHRNA	  
The	  original	  high	  throughput	  screen	  was	  conducted	  using	  siRNAs	  as	  a	  
means	  of	  inhibiting	  protein	  expression	  and	  this	  needs	  to	  be	  validated	  using	  
alternatives	  such	  as	  short	  hairpin	  RNAs	  (shRNAs)	  [27].	  Small	  interfering	  
RNAs	  (siRNAs)	  are	  chemically	  synthesized	  and	  double	  stranded	  whereas	  
shRNAs	  are	  continually	  expressed	  from	  the	  cell	  after	  a	  vector	  is	  inserted	  
into	  the	  cell	  DNA	  [58].	  In	  order	  to	  be	  incorporated	  into	  the	  cell,	  an	  envelope	  
protein	  and	  a	  packaging	  vector	  create	  the	  virus	  and	  are	  assembled	  to	  
contain	  the	  shRNA	  plasmid	  vector	  by	  being	  assembled	  during	  transfection	  
in	  293FT	  cells.	  The	  envelope	  protein	  of	  the	  virus	  we	  use	  is	  vesicular	  
stomatitis	  viral	  glycoprotein	  (VSVG)	  and	  the	  packaging	  vector	  is	  psPAX2.	  
psPAX2	  contains	  RNA	  polymerase	  III,	  reverse	  transcriptase	  (RT),	  integrase	  
and	  protease	  which	  help	  the	  shRNA	  incorporate	  to	  the	  DNA	  of	  the	  host	  and	  
facilitate	  expression.	  The	  shRNA	  is	  part	  of	  a	  GIPZ	  transfer	  plasmid	  that	  also	  
contains	  green	  fluorescent	  protein	  (GFP)	  and	  antibiotic	  resistance	  proteins.	  
After	  an	  shRNA	  vector	  is	  incorporated	  into	  a	  cell,	  shRNA	  is	  synthesized	  in	  
the	  nucleus,	  and	  then	  modified	  by	  Drosha	  and	  Dicer	  protein	  complexes.	  
This	  prepares	  the	  pre-­‐shRNA	  for	  the	  RNA-­‐induced	  silencing	  complex	  (RISC)	  
which	  has	  an	  Argonaute	  endonuclease	  subunit	  that	  primes	  the	  shRNA	  to	  
target	  the	  shRNA’s	  complementary	  mRNA	  and	  cleave	  it	  (Figure	  8)	  [59,60].	  
In	  this	  manner,	  mRNA	  is	  cleaved	  and	  degraded,	  which	  prevents	  the	  target	  
gene	  from	  being	  translated	  into	  protein.	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Figure	  8	   -­‐	  The	  course	  of	   shRNA	   into	   the	  nucleus	  and	  subsequent	  processing	  
to	   cleave	   the	   mRNA.	   Drosha,	   Exportin5,	   Dicer	   and	   RISC	   protein	   complexes	  
contribute	   to	   produce	   functional	   shRNA	   with	   the	   ability	   to	   cleave	   the	   target	  
mRNA	  [61].	  
The	  loading	  of	  siRNA	  to	  RISC	  is	  reported	  as	  10x	  less	  effective	  than	  that	  of	  
shRNA.	  48	  hrs	  post	  transduction;	  siRNA	  is	  reported	  to	  degrade	  so	  that	  less	  
than	  1%	  of	  the	  introduced	  double	  stranded	  duplex	  remains.	  shRNA	  
however	  is	  	  continuously	  expressed	  by	  the	  host	  cell	  making	  the	  shRNA	  
knockdown	  more	  durable	  [61].	  These	  weaknesses	  in	  siRNA	  promote	  shRNA	  
as	  a	  more	  reliable	  mechanism	  to	  carry	  out	  RNA	  interference.	  	  
The	  high	  transfection	  efficiency	  and	  integration	  of	  exogenous	  DNA	  of	  the	  
lentiviral	  vector	  delivery	  system	  promotes	  shRNA	  as	  the	  preferable	  method	  
of	  RNA	  interference.	  shRNA	  is	  introduced	  via	  lentiviral	  vector	  transduction,	  
along	  with	  lipofectamine,	  psPAX2	  as	  a	  packaging	  vector,	  and	  the	  G	  glycol-­‐
protein	  of	  the	  rhabdovirus	  vesicular	  stomatitis	  virus	  (VSVG)	  as	  an	  envelope	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protein	  that	  aids	  in	  transfection	  efficiency	  by	  forming	  fusogenic	  liposomes	  
[62-­‐64].	  This	  particular	  method	  has	  been	  considered	  dangerous	  to	  
laboratory	  personnel	  in	  the	  past.	  Further	  reviews	  promote	  their	  use	  as	  safe	  
in	  a	  secure	  lab	  environment,	  but	  should	  never	  have	  a	  clinical	  use	  [61,65].	  	  
They	  do	  however	  provide	  a	  great	  tool	  that	  can	  identify	  therapeutic	  targets	  
that	  can	  aid	  cancer	  research.	  
1.4.2 MCF10A	  CELLS	  WITH	  AND	  WITHOUT	  CDH1	  EXPRESSION	  
The	  MCF10A	  cell	  line	  was	  named	  after	  the	  Michigan	  Cancer	  Foundation,	  the	  
institute	  that	  isolated	  it.	  The	  spontaneously	  immortalised	  MCF10A	  (A	  for	  
attached)	  cell	  line	  is	  from	  a	  36-­‐year-­‐old	  woman	  who	  had	  no	  family	  history	  
of	  breast	  cancer.	  MCF10A	  cells	  are	  non-­‐tumorigenic,	  do	  not	  require	  a	  pro-­‐
carcinogen,	  have	  no	  SV40	  genetic	  material,	  and	  the	  karyotype	  is	  near-­‐
diploid	  with	  minimal	  rearrangement	  [66].	  MCF10As	  are	  limited	  as	  a	  model	  
of	  mammary	  epithelial	  cells	  as	  they	  need	  to	  be	  organised	  into	  a	  three-­‐
dimensional	  basement	  membrane	  to	  be	  a	  true	  replicate	  of	  pathogenesis,	  
but	  they	  are	  sufficient	  models	  for	  providing	  proof	  of	  principle	  of	  a	  synthetic	  
lethal	  effect	  [67].	  
An	  isogenic	  MCF10A	  CDH1-­‐/-­‐	  cell	  line	  was	  created	  via	  zinc	  finger	  nuclease	  
(Sigma-­‐Aldrich).	  The	  knockout	  of	  CDH1	  was	  caused	  by	  a	  4	  bp	  homozygous	  
deletion	  in	  exon	  11	  resulting	  in	  a	  frameshift,	  a	  premature	  stop	  codon,	  and	  a	  
truncated	  E-­‐cadherin	  protein	  that	  was	  confirmed	  by	  immuno-­‐fluorescence.	  	  
The	  CDH1-­‐/-­‐	  cells	  have	  the	  following	  characteristics:	  a	  rounder	  morphology,	  
less	  dense	  microtubule	  network	  and	  slower	  migration	  time	  [2].	  One	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confounding	  factor	  in	  all	  future	  comparisons	  between	  these	  two	  cell	  lines	  is	  
that	  the	  CDH1-­‐/-­‐	  cells	  have	  a	  significant	  change	  in	  gene	  expression.	  This	  
includes	  an	  expected	  compensating	  upregulation	  of	  desmosomes,	  tight	  
junctions	  and	  gap	  junction	  genes	  because	  of	  the	  deficiency	  of	  E-­‐cadherin	  in	  
forming	  adherens	  junctions	  [2].	  Further	  research	  on	  other	  models	  will	  be	  
needed	  to	  validate	  any	  synthetically	  lethal	  combinations	  that	  occur	  on	  the	  
MCF10A	  cells	  with	  and	  without	  CDH1	  expression,	  especially	  considering	  
that	  HDGC	  occurs	  in	  gastric	  as	  well	  as	  breast	  cells.	  
1.4.3 POLOXIPAN	  
Polo-­‐like	  kinases	  interact	  with	  the	  cyclin-­‐dependent	  kinases	  and	  Aurora	  
kinases	  in	  regulation	  of	  the	  cell	  cycle	  and	  as	  such,	  small	  molecule	  inhibits	  
for	  PLK1	  were	  identified.	  PLK1	  binds	  directly	  with	  p53,	  causing	  the	  tumour	  
suppressor	  to	  degrade.	  PLK1	  also	  reduced	  the	  activity	  of	  other	  pro-­‐
apoptotic	  proteins:	  p21,	  p73	  and	  BAX	  [47].	  PLK1	  inhibitors	  are	  therefore	  a	  
plausible	  and	  valid	  solution	  to	  several	  cancers.	  There	  are	  current	  PLK1	  
inhibitors	  in	  clinical	  development,	  which	  is	  controversial	  due	  to	  research	  
that	  shows	  they	  also	  inhibit	  PLK2	  and	  PLK3	  at	  similar	  concentrations.	  	  
As	  research	  continues	  to	  indicate	  that	  PLK3	  is	  a	  tumour	  suppressor,	  it	  is	  
concerning	  that	  PLK1	  inhibitors	  are	  be	  limiting	  PLK3s	  tumour	  suppressor	  
role.	  Poloxipan	  is	  a	  pan-­‐specific	  PLK	  inhibitor	  that	  is	  not	  in	  any	  current	  
clinical	  trials.	  Poloxipan’s	  IC50	  for	  PLK1	  is	  3.2µM,	  and	  for	  PLK3	  it	  is	  3.0µM	  
[3].	  Out	  of	  the	  many	  PLK	  inhibitors,	  this	  one	  was	  the	  only	  one	  to	  show	  more	  
inhibition	  for	  PLK3	  than	  for	  PLK1	  as	  most	  research	  is	  aimed	  at	  avoiding	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inhibition	  of	  PLK3.	  Poloxipan	  is	  currently	  the	  most	  suitable	  PLK3	  protein	  
inhibitor	  to	  investigate	  if	  PLK3	  is	  in	  a	  synthetic	  lethal	  relationship	  with	  E-­‐
cadherin.	  	  
1.4.4 WORTMANNIN	  
Wortmannin	  is	  a	  well-­‐characterised	  Phosphoinositide	  3-­‐kinase	  (PI3K)	  
inhibitor	  that	  is	  used	  as	  an	  in	  vivo	  anti-­‐tumour	  therapy	  studies	  [68].	  
Although	  wortmannin	  is	  a	  potent	  PI3K	  inhibitor	  it	  is	  shown	  to	  inhibit	  a	  
broad	  range	  of	  substrates	  including	  PLK1	  and	  PLK3	  at	  the	  concentrations	  
that	  it	  would	  be	  used	  to	  inhibit	  PI3K.	  The	  IC50	  values	  for	  PI3K	  are	  reported	  
to	  be	  at	  3nM	  and	  for	  PLK3	  were	  48nM	  [69].	  	  
1.5 HYPOTHESIS	  
We	  hypothesize	  that	  PLK3	  is	  a	  synthetic	  lethal	  partner	  of	  CDH1.	  Targeting	  
PLK3	  is	  predicted	  to	  reduce	  the	  viability	  of	  CDH1-­‐/-­‐	  cells	  while	  MCF10A	  cells	  
will	  remain	  viable.	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1.6 EXPERIMENTAL	  OVERVIEW	  
	  
	   	  
shRNA	  PLK3	  Knockdown	  
Amplify	  plasmid	  in	  E.coli	  
Extract	  shRNA	  plasmid	  
Transfect	  plasmid	  with	  
psPAX2	  and	  VSVG	  in	  293FT	  
cells	  
Titre	  the	  shRNA	  lenhvirus	  
Transduce	  MCF10A	  and	  
CDH1-­‐/-­‐	  cells	  with	  the	  
shRNA	  
Calculate	  Cell	  Viability	  
Confirm	  PLK3	  Knockdown	  
by	  RT-­‐qPCR	  
PLK3	  Drug	  Inhibi[on	  
Drug	  MCF10A	  and	  CDH1-­‐/-­‐	  
cells	  and	  Imaging	  in	  
IncuCyte	  
Calculate	  Cell	  Viability	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2  METHODS	  
“Just	  keep	  trying”	  –	  Jeffrey	  R	  Holland	  
2.1 MATERIALS	  
2.1.1 REAGENTS	  
The	  water	  used	  in	  all	  experiments	  was	  ultrapure	  water	  of	  “Type	  1”	  quality	  
(resistivity	  18.2MΩ·cm	  at	  25°C)	  prepared	  using	  a	  Millipore	  Corporation	  
water	  filtration	  station.	  
0.05%	  Trypsin	  Solution	  
293FT	  Cell	  Line	  –	  Donated	  Dr	  S.	  Hughes,	  NZ	  
Agar	  (A0949)	  –	  AppliChem,	  USA	  
Ampicillin	  –	  Sigma-­‐Aldrich,	  USA	  
CDH1-­‐/-­‐	  Cell	  Line	  –	  Sigma-­‐Aldrich,	  USA	  	  
Cholera	  Toxin	  –	  Sigma-­‐Aldrich,	  USA	  	  
Dimethyl	  Sulfoxide	  (DMSO)	  –	  Sigma-­‐Aldrich,	  USA	  	  
Dulbecco's	  Modified	  Eagle's	  Medium	  (DMEM)	  –	  Invitrogen,	  USA	  
Dulbecco's	  Modified	  Eagle's	  Medium	  and	  F12	  Medium	  (DMEM-­‐F12)	  –	  
Invitrogen,	  USA	  	  
Ethanol	  (EtOH)	  –	  Lab	  Supplies,	  NZ	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Foetal	  Bovine	  Serum	  (FBS)	  –	  Invitrogen,	  USA	  	  
Glycerol	  –	  Scharlau,	  Australia	  	  	  
Hoechst	  33342	  Dye	  –	  Sigma-­‐Aldrich,	  USA	  	  	  
Horse	  Serum	  –	  Invitrogen,	  USA	  	  
Human	  Epidermal	  Growth	  Factor	  (EGF)	  –	  PeproTech,	  USA	  
Hydrocortisone	  –	  Sigma-­‐	  Aldrich,	  USA	  	  
Insulin	  (Actrapid®	  Penfill®	  100iu/mL)	  –	  Novo	  Nordisk®,	  Denmark	  
KAPA	  SYPR	  FAST	  RT-­‐qPCR	  Kit	  –	  Kapa	  Biosystems,	  South	  Africa	  	  
Kapa	  Universal	  DNA	  Ladder	  -­‐	  Kapa	  Biosystems,	  South	  Africa,	  USA	  
L-­‐Glutamine	  –	  Invitrogen,	  USA	  
Lipofectamine®	  2000	  Transfection	  Reagent	  –	  Life	  Technologies,	  USA	  
Lysogeny	  Broth	  (LB)	  –	  Prepared	  In	  Lab	  (Appendix	  5.3.2)	  
MCF10A	  Cell	  Line	  –	  Sigma-­‐Aldrich,	  USA	  	  
Non-­‐Essential	  Amino	  Acids	  –	  Invitrogen,	  USA	  
Opti-­‐MEM	  –	  Life	  Technologies,	  USA	  
Paraformaldehyde	  –	  VWR	  Chemicals,	  NZ	  
pGIPZ	  shRNA	  PLK3,	  Non-­‐Silencing	  And	  No	  Insert	  Constructs	  –	  Dharmacon,	  
USA	  
Phosphate	  Buffered	  Saline	  (Dulbecco	  A)	  Tablets	  –	  Oxoid	  Limited,	  UK	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Poloxipan	  –	  Vitas-­‐M	  Laboratory,	  Hong	  Kong	  
PrimeScript	  RT	  Reagent	  Kit	  (Perfect	  Real	  Time)	  –	  TAKARA	  BIO	  INC.,	  Japan.	  
Propidium	  Iodide	  –	  Thermo	  Fisher	  Scientific,	  USA	  
psPAX2	  Lentiviral	  Packaging	  Plasmid	  –	  Addgene,	  UK	  	  
Puromycin	  –	  InvivoGen,	  USA	  
RNAGEM	  Tissue	  Plus	  Kit	  –	  ZyGEM,	  New	  Zealand	  
Saponin	  –	  Donated	  By	  Dearden	  Lab,	  University	  Of	  Otago,	  NZ	  
Sodium	  Chloride	  –	  Scharlau,	  Spain	  
Sodium	  Pyruvate	  –	  Invitrogen,	  USA	  
Trypan	  Blue	  –	  Sigma-­‐Aldrich,	  USA	  	  
Tryptone	  –	  Scharlau,	  Spain	  
Ultra-­‐Pure	  Distilled	  Water	  –	  Invitrogen,	  USA	  
Viraclean	  –	  Whiteley	  Medical,	  Australia	  
VSVG	  Lentiviral	  Envelope	  Plasmid	  –	  Addgene,	  UK	  
Wortmannin	  –	  Selleckchem,	  USA	  
Yeast	  Extract	  –	  Merck,	  Germany	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2.1.2 EQUIPMENT	  
0.2mL	  Semi-­‐Skirted	  96-­‐Well	  PCR	  Plate	  –	  Thermo	  Scientific,	  UK	  
0.2mM	  Hydrophilic	  Syringe	  Filter	  –	  Ahlstrom,	  Germany	  
0.22mM	  Polyethersulfone	  Vacuum	  Filter	  System	  –	  Jet	  Bio-­‐Filtration,	  China	  	  
0.45mM	  Polyvinylidene	  fluoride	  Syringe	  Filter	  –	  Mereck,	  Ireland	  
0.6mL	  Microtube	  –	  Axygen,	  USA	  	  
1mL	  Syringe	  –	  BD,	  Singapore	  
1.5mL	  Microtube	  –	  Axygen,	  USA	  	  
10mL	  Serological	  Pipet	  –	  Jet	  Bio-­‐	  Filtration,	  China	  
10mL	  Syringe	  –	  BD,	  Singapore	  
15mL	  Falcon	  Centrifuge	  Tubes	  –	  Greiner	  Bio-­‐One,	  Germany	  
20mL	  Syringe	  –	  BD,	  USA	  
200mL	  Schott	  bottle	  –	  Schott	  North	  America,	  USA	  
25mL	  CELLSTAR	  Cell	  Culture	  Flasks	  –	  Greiner	  Bio-­‐One,	  Germany	  
25mL	  Serological	  Pipet	  –	  Jet	  Bio-­‐Filtration,	  China	  
384-­‐Well	  Assay	  Plate	  3707,	  White	  with	  Clear	  Bottom	  –	  Corning,	  USA	  
400mL	  Schott	  bottle	  –	  Schott	  North	  America,	  USA	  
50mL	  Falcon	  Centrifuge	  Tubes	  –	  Greiner	  Bio-­‐One,	  Germany	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75mL	  CELLSTAR	  Cell	  Culture	  Flasks	  –	  Greiner	  Bio-­‐One,	  Germany	  
96-­‐Well	  Assay	  Plate	  3603	  –	  Corning,	  USA	  	  
94mm	  ×	  16mm,	  vented	  disposable	  petri	  dish	  with	  lid	  –	  Brand®,	  Germany	  
ABI	  Prism	  7900	  HT	  –	  Applied	  Biosystems,	  USA	  
C1000™	  ThermoCycler	  –	  Bio-­‐Rad,	  USA	  	  
Cell	  Culture	  Dishes	  100x20mm	  –	  Greiner	  Bio-­‐One,	  Germany	  
Centra	  3c	  Centrifuge	  –	  International	  Equipment	  Company,	  UK	  
Centrifuge	  5810	  –	  Eppendorf,	  Germany	  
CO2	  Cell	  Culture	  Incubator	  –	  Binder,	  Germany	  	  
Cryo	  Vials	  –	  Nunc,	  Denmark	  
Cytation	  5	  Cell	  Imaging	  Multimode	  Reader	  –	  BioTek,	  USA	  
Cytell	  Cell	  Imaging	  System	  –	  GE	  Lifesciences,	  USA	  
Double-­‐Chambered	  Cell-­‐Counting	  Slide	  –	  Bio-­‐Rad,	  USA	  
IEC	  Centra-­‐3C	  Centrifuge	  –	  International	  Equipment	  Company,	  USA	  
IncuCyte	  ZOOM	  System	  –	  Essen	  Bioscience,	  USA	  
Inoculating	  Loops	  –	  Nunc,	  Denmark	  
Magnetic	  Stirrer	  MR	  001	  –	  Heidolph,	  Germany	  
Microamp	  Optical	  384-­‐Well	  Reaction	  Plate	  –	  Life	  Technologies,	  USA	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Milli-­‐Q	  Ultrapure	  Water	  Purification	  System	  –	  Millipore,	  USA	  	  
NanoDrop	  ND-­‐1000	  Spectrophotometer	  –	  NanoDrop	  Technologies,	  USA	  	  
NucleoBond	  Xtra	  Midi	  Plasmid	  DNA	  purification	  –	  	  Macherey-­‐Nagel,	  
Germany	  
NucleoSpin	  Plasmid	  DNA	  purification	  –	  Macherey-­‐Nagel,	  Germany	  
Olympus	  CK2	  Microscope	  –	  Olympus,	  Japan	  
Pasteur	  Pipettes	  –	  Hirschmann,	  Germany	  
Solution	  Basin	  –	  Biologix,	  Group	  
TC10	  Automated	  Cell	  Counter	  –	  Bio-­‐Rad,	  USA	  	  
Thermal	  Seal,	  Real-­‐Time	  PCR	  Optical	  Plastic	  Sheet	  –	  Interlab	  Ltd,	  NZ	  
Tissue	  Culture	  Hood	  –	  EMAIL,	  Australia	  	  
Water	  Bath	  –	  Semco,	  USA	  
2.2 CELL	  CULTURE	  
2.2.1 293FT	  CELLS	  
293FT	  cells	  were	  used	  for	  the	  production	  of	  the	  shRNA	  lentivirus	  as	  their	  
SV40	  large	  T	  antigen	  allows	  for	  high	  protein	  expression.	  They	  are	  derived	  
from	  293F	  human	  embryonic	  kidney	  cells	  and	  provide	  a	  high	  lentiviral	  
titre.	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2.2.1.1 293FT	  CELL	  MEDIA	  	  
The	  following	  components	  were	  filtered	  through	  a	  500mL	  0.22µm	  
Polyethersulfone	  (PES)	  Vacuum	  Bottle	  Filter	  (Jet	  Bio-­‐Filtration):	  DMEM,	  
FBS,	  L-­‐Glutamine,	  Sodium	  pyruvate	  and	  Non-­‐essential	  AA	  (Table	  3).	  
Table	  3	  -­‐	  Constituents	  of	  the	  293FT	  media.	  
Constituents	   Concentration	  
DMEM	  (500mL)	   88%	  
FBS	  (50mL)	   8.8%	  
L-­‐Glutamine	  (5mL)	   6mM	  
Sodium	  pyruvate	  (5mL)	   1mM	  
Non-­‐essential	  AA	  (5mL)	   0.1mM	  
	  
2.2.1.2 293FT	  CELL	  RECOVERY	  	  
293FT	  cells	  stored	  in	  liquid	  Nitrogen	  at	  a	  low	  passage	  stock	  (12	  –	  13)	  were	  
removed	  and	  warmed	  in	  a	  37°C	  water	  bath.	  When	  defrosted	  they	  were	  
added	  to	  a	  T25	  flask	  with	  fresh	  warmed	  media.	  Cells	  were	  passaged	  the	  
following	  day	  to	  a	  T75	  flask.	  
2.2.1.3 PASSAGING	  293FT	  CELLS	  
293FT	  cells	  are	  very	  sensitive	  and	  therefore	  must	  be	  handled	  with	  utmost	  
care,	  as	  rough	  handling	  will	  dislodge	  the	  cells.	  Complete	  confluence	  was	  
avoided	  as	  the	  cells	  began	  to	  peel	  away	  and	  form	  sheets.	  To	  passage,	  cells	  
were	  incubated	  in	  phosphate	  buffer	  saline	  (PBS)	  with	  0.05%	  trypsin	  at	  
room	  temperature	  for	  5min.	  Fresh	  media	  was	  then	  added	  to	  wash	  off	  cells	  
and	  transfer	  to	  a	  15mL	  falcon.	  Cells	  were	  spun	  at	  500rpm	  for	  5	  min	  to	  
pellet.	  Supernatant	  was	  aspirated	  and	  the	  pellet	  was	  resuspended	  in	  5mL	  
media.	  1x106	  cells	  were	  seeded	  in	  a	  T75	  flask	  or	  10cm	  cell	  culture	  to	  reach	  
90%	  confluence	  in	  4	  days.	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2.2.2 MCF10A	  CELLS	  
MCF10A	  cells	  and	  their	  isogenic	  partner	  CDH1-­‐/-­‐	  (Sigma-­‐Aldrich)	  were	  used	  
to	  model	  non-­‐tumourgenic	  epithelial	  cells	  for	  this	  study.	  MCF10A	  cells	  are	  
diploid	  and	  dependent	  on	  exogenous	  growth	  factors	  to	  proliferate	  and	  are	  
considered	  a	  normal	  epithelial	  cell	  model.	  Coming	  from	  breast	  tissue,	  
MCF10A	  are	  biologically	  relevant	  as	  HDGC	  predisposes	  female	  CDH1	  germ	  
line	  mutation	  carriers	  to	  LBC.	  	  
2.2.2.1 MCF10A	  CELL	  MEDIA	  
The	  following	  components	  were	  filtered	  through	  a	  500mL	  0.22µm	  
Polyethersulfone	  (PES)	  Vacuum	  Bottle	  Filter	  (Jet	  Bio-­‐Filtration)	  (Table	  4).	  
Table	  4	  -­‐	  Constituents	  of	  the	  MCF10A	  media.	  
Constituents	   Concentration	  
DMEM/F12	  (500mL)	   95%	  
Horse	  Serum	  (25mL)	   5%	  
Insulin	  (1.4mL)	   (10µg/mL)	  
Hydrocortisone	  (250µL)	   (0.5µg/mL)	  
EGF	  (100µL)	   (20ng/mL)	  
	  
2.2.2.2 MCF10A	  CELL	  RECOVERY	  
MCF10A	  and	  CDH-­‐/-­‐	  cells	  were	  stored	  in	  liquid	  nitrogen	  at	  a	  passage	  of	  4-­‐5.	  
They	  were	  warmed	  in	  the	  37°C	  water	  bath	  before	  being	  added	  to	  10mL	  of	  
MCF10A	  media	  in	  a	  15mL	  tube.	  The	  15mL	  falcon	  was	  centrifuged	  at	  
900rpm	  and	  the	  supernatant	  discarded.	  Cells	  were	  resuspended	  in	  
complete	  MCF10A	  media	  and	  were	  all	  added	  to	  a	  T25	  cell	  culture	  flask.	  
After	  24	  hrs	  the	  morphology	  confirmed	  the	  difference	  between	  the	  
MCF10A	  and	  CDH-­‐/-­‐	  cell	  lines	  as	  MCF10A	  grow	  faster	  and	  are	  less	  clumped.	  
Cells	  are	  thereafter	  passaged	  every	  3-­‐4	  days	  before	  reaching	  confluence.	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2.2.2.3 PASSAGING	  MCF10A	  CELLS	  
To	  passage	  the	  MCF10A	  and	  CDH-­‐/-­‐	  cells,	  they	  were	  rinsed	  in	  PBS	  before	  
leaving	  for	  20	  minutes	  (min)	  at	  37°C	  in	  0.05%	  trypsin	  to	  lift	  the	  cells.	  Media	  
was	  added	  to	  wash	  the	  cells	  off	  the	  plate	  and	  the	  cells	  were	  moved	  to	  a	  
15mL	  tube.	  The	  tubes	  were	  centrifuged	  at	  800rpm	  for	  5	  min	  and	  the	  
supernatant	  discarded.	  Fresh	  37°C	  media	  was	  added	  to	  resuspend	  the	  
pellet	  and	  the	  cell	  density	  counted	  using	  the	  double-­‐chambered	  cell	  
counting	  slide	  in	  the	  TC10	  automated	  cell	  counter	  (Bio-­‐Rad).	  The	  MCF10A	  
cells	  were	  seeded	  at	  4000	  cells/cm2	  in	  either	  a	  T25	  or	  T75	  flask	  and	  CDH1-­‐/-­‐	  
cells	  were	  seeded	  at	  6000cells/cm2,	  as	  they	  took	  longer	  to	  grow.	  Cells	  were	  
incubated	  at	  37°C	  for	  four	  days	  at	  which	  they	  would	  reach	  90%	  confluence.	  
2.3 CREATING	  THE	  SHRNA	  LENTIVIRUS	  
The	  shRNA	  (Dharmacon)	  are	  packaged	  in	  a	  GIPZ	  plasmid	  and	  supplied	  in	  
Escherichia	  coli	  (E.coli).	  The	  GIPZ	  plasmid	  contains	  GFP	  for	  confirmation	  of	  
the	  transduction.	  It	  also	  contains	  ampicillin	  and	  puromycin	  resistance	  
genes	  that	  help	  isolate	  and	  select	  for	  the	  cells	  or	  E.coli	  which	  contain	  the	  
plasmid.	  The	  plasmids	  were	  packaged	  in	  293FT	  cells,	  and	  a	  titre	  was	  
calculated	  in	  MCF10A	  cells.	  	  
2.3.1 PLASMID	  PREPARATION	  
The	  following	  GIPZ	  plasmids	  contained	  in	  individual	  E.coli	  colonies	  were	  
used	  in	  these	  experiments:	  10	  shRNA	  with	  individual	  PLK3	  and	  Non-­‐
silencing,	  targeting	  sequences	  (Table	  5	  and	  Figure	  9),	  vesicular	  stomatitis	  
	   45	  
viral	  glycoprotein	  (VSVG)	  and	  the	  second-­‐generation	  packaging	  vector	  
(psPAX2).	  Glycerol	  stocks	  of	  the	  E.coli	  were	  stored	  at	  -­‐80°C	  and	  using	  an	  
inoculating	  loop	  they	  were	  streaked	  on	  separate	  lysogeny	  broth	  and	  agar	  
plates	  with	  100µg/mL	  ampicillin	  for	  each	  specific	  shRNA	  (Chapter	  5.1	  for	  
Lysogeny	  broth	  agar	  plates	  and	  5.2	  for	  Lysogeny	  broth	  components).	  
Ampicillin	  was	  used	  to	  select	  for	  E.coli	  containing	  the	  plasmid.	  Plates	  were	  
incubated	  overnight	  at	  37°C.	  The	  following	  day	  only	  a	  single	  colony	  from	  
each	  plate	  was	  inoculated	  to	  a	  separate	  tube	  with	  15mL	  lysogeny	  broth	  and	  
100µg/mL	  ampicillin	  solution	  and	  was	  shaken	  overnight	  at	  37°C.	  
Table	   5	   -­‐	   shRNA	   sequences.	  The	  shRNA	  used	   in	   these	  experiments	  named	  after	  
the	   well	   they	   originated	   from,	   their	   target	   gene	   and	   the	   sequence	   that	   targets	  
that	  gene.	  
Origin Target Sequence of shRNA 
E4	   PLK3	   AGTGAACCTGCTTGATGCA	  
E5	   PLK3	   AGTGCACAGTCTTTCTGTT	  
E6	   PLK3	   TGAAGAGCACAGCCACACG	  
E7	   PLK3	   ACTCTTCTTCTTTCTGCCA	  
E8	   PLK3	   TGTAGTGCACAGTCTTTCT	  
E9	   PLK3	   AGCTGGGAGCTAAGGCTCA	  
E10	   PLK3	   TTAGGATCTTCTCGCGCTG	  
E11	   PLK3	   TCAGGTGCTGTCTCTACCA	  
E12	   PLK3	   TTTCTCAGAGCACAAAGGG	  
F1	   PLK3	   AGTGGTCCATAAATAACGC	  
Non-­‐Silencing	   -­‐	   CTTACTCTCGCCCAAGCGAGAG	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Figure	   9	   -­‐	   shRNA	   sequences	   targeting	   the	   CDH1-­‐/-­‐	   gene.	   The	   transcript	   of	   CDH1	  
displayed	  with	  the	  exons	  as	  green	  blocks	  and	  introns	  as	  the	  connecting	  lines.	  The	  
vertical	   blue	   lines	   indicate	   the	   sequences	   of	   shRNA	   (labelled	  by	   their	   identifier)	  
that	  match	  on	   this	   gene.	  This	  was	  performed	  using	   an	  online	   tool	   “siRNA	   check”	  
developed	  by	  Silico	  Solutions.	  
To	  obtain	  a	  high	  quantity	  of	  the	  VSVG	  and	  psPAX2	  plasmids,	  the	  spin	  
column	  based	  NucleoBond	  Xtra	  Midi	  Prep	  kit	  (Macherey-­‐Nagel)	  was	  used	  
to	  separate	  the	  plasmids	  from	  the	  E.coli.	  For	  the	  PLK3	  shRNA,	  the	  
NucleoSpin	  plasmid	  DNA	  purification	  kit	  (MACHEREY-­‐NAGEL)	  spin	  column	  
protocol	  was	  used.	  
The	  amplified	  E.coli	  in	  the	  lysogeny	  broth	  and	  ampicillin	  culture	  was	  
centrifuged	  to	  form	  a	  pellet	  and	  the	  supernatant	  discarded.	  The	  NucleoSpin	  
plasmid	  DNA	  purification	  protocol	  was	  then	  followed	  except	  after	  
resuspending	  the	  pellet;	  two	  200µL	  aliquots	  of	  the	  suspended	  pellet	  in	  
buffer	  were	  extracted.	  Each	  shRNA	  plasmid	  then	  had	  two	  quantities	  that	  
proceeded	  through	  the	  protocol,	  which	  increased	  the	  quantity.	  
To	  elute	  the	  plasmid	  DNA	  out	  of	  the	  spin	  column,	  the	  elution	  buffer	  was	  left	  
to	  incubate	  for	  15	  min	  rather	  than	  just	  one	  as	  previous	  optimisation	  found	  
this	  yielded	  greater	  quantity.	  Centrifuging	  the	  column	  and	  repeating	  the	  
elution	  was	  gave	  a	  greater	  plasmid	  yield.	  This	  was	  repeated	  with	  the	  two	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aliquots	  from	  each	  E.coli,	  producing	  two	  quantities	  with	  a	  final	  volume	  of	  
110µL.	  The	  two	  volumes	  were	  combined	  giving	  a	  greater	  final	  quantity.	  
2.3.2 TRANSFECTION	  
In	  order	  to	  produce	  an	  shRNA	  lentivirus,	  the	  shRNA,	  a	  packaging	  vector	  
psPAX2	  and	  an	  envelope	  vector	  VSVG	  were	  transfected	  into	  293FT	  cells	  to	  
package	  the	  pGIPZ	  shRNA	  plasmid.	  5.4x106	  293FT	  cells	  were	  seeded	  in	  a	  
T75	  cell	  culture	  flask	  in	  293FT	  media	  24	  hrs	  before	  transfecting	  the	  
plasmids.	  The	  following	  day,	  the	  concentration	  of	  extracted	  plasmids	  
(Chapter	  2.3.1)	  was	  measured	  using	  the	  NanoDrop	  ND-­‐1000	  
Spectrophotometer	  to	  determine	  the	  volume	  required	  to	  add	  18.56µg	  
shRNA	  plasmid,	  9.6µg	  psPAX2	  and	  4.8µg	  VSVG	  to	  each	  transfection.	  These	  
were	  mixed	  in	  1mL	  of	  filtered	  Opti-­‐MEM	  solution,	  a	  media	  derived	  from	  
Eagle's	  Minimum	  Essential	  Media	  that	  aids	  transfection,	  due	  an	  increased	  
amount	  of	  HEPES	  buffer	  that	  aids	  the	  transfection.	  	  Separately,	  55.7µL	  
Lipofectamine	  2000	  was	  added	  to	  944.2µL	  of	  Opti-­‐MEM,	  in	  a	  separate	  tube	  
for	  each	  shRNA	  lentivirus	  to	  be	  created.	  The	  1mL	  solution	  containing	  the	  
shRNA,	  psPAX2	  and	  VSVG	  was	  filtered	  through	  a	  0.22µm	  hydrophilic	  filter	  
into	  the	  1mL	  lipofectamine	  and	  Opti-­‐MEM	  mix	  and	  incubated	  at	  room	  
temperature	  for	  20	  min.	  This	  allowed	  for	  the	  liposome	  to	  encase	  the	  
plasmids	  that	  aids	  uptake	  by	  helping	  the	  vessels	  cross	  the	  cell	  membrane.	  
The	  media	  was	  removed	  from	  the	  293FT	  cells	  and	  were	  washed	  in	  PBS.	  
Opti-­‐MEM	  with	  5%	  foetal	  bovine	  serum	  (FBS)	  was	  added,	  along	  with	  the	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liposomes	  containing	  the	  shRNA,	  psPAX2,	  VSVG.	  Plates	  were	  returned	  to	  
the	  37°C	  incubator.	  	  
After	  a	  further	  24	  hrs,	  media	  was	  removed	  from	  the	  flask	  followed	  by	  a	  
gentle	  PBS	  wash.	  This	  was	  replaced	  with	  6mL	  complete	  293FT	  cell	  media.	  
At	  48	  hrs	  post	  transfection,	  the	  6mL	  of	  media	  from	  the	  293FT	  cells	  was	  
collected	  and	  centrifuged	  for	  15	  min	  at	  3000rpm.	  The	  supernatant	  
containing	  the	  lentivirus	  was	  filtered	  through	  a	  0.45μM	  Polyvinylidene	  
fluoride	  filter	  and	  aliquoted	  into	  10	  lots	  of	  500µL	  to	  be	  stored	  at	  -­‐80°C.	  
Each	  500µL	  was	  used	  only	  once	  to	  remove	  any	  effects	  of	  repeated	  thawing	  
and	  freezing.	  
2.3.3 TITRE	  
A	  titration	  determines	  the	  amount	  of	  viral	  transducing	  units	  (TU)	  contained	  
in	  the	  harvested	  virus.	  The	  titre	  was	  determined	  by	  measuring	  the	  quantity	  
of	  MCF10A	  cells	  expressing	  the	  GFP	  reporter	  from	  the	  shRNA	  plasmid.	  A	  
serial	  dilution	  created	  a	  range	  of	  concentrations	  that	  the	  amount	  of	  TU/mL	  
was	  derived	  from.	  At	  low	  concentrations	  of	  virus,	  for	  every	  GFP	  positive	  
cell,	  there	  is	  only	  one	  transducing	  unit	  for	  that	  cell.	  At	  higher	  concentration,	  
multiple	  transducing	  units/cell	  may	  occur,	  which	  would	  skew	  the	  count	  of	  
TU/mL.	  
MCF10A	  cells	  were	  seeded	  at	  4x104cells/well	  in	  100µL	  into	  a	  96	  well	  plate	  
with	  black	  walls	  and	  a	  clear	  bottom	  compatible	  with	  fluorescent	  imaging.	  
After	  24	  hrs,	  the	  lentivirus	  (Chapter	  2.3)	  was	  diluted	  by	  a	  factor	  of	  2	  five	  
times	  to	  provide	  a	  range	  of	  six	  concentrations	  (Figure	  10).	  100µL	  of	  each	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dilution	  was	  added	  to	  the	  cells	  in	  their	  100µL	  of	  media	  creating	  a	  further	  2	  
fold	  dilution	  to	  have	  a	  final	  dilution	  range	  of	  1:1,	  1:3,	  1:7,	  1:15,	  1:31,	  1:63.	  A	  
additional	  well	  of	  100µL	  media	  only	  served	  as	  a	  negative	  control.	  
	  	   	  
Figure	   10	   -­‐	   Lentivirus	   dilution	   for	   titre.	   Harvested	   lentivirus	   was	  
diluted	  and	  added	  to	  the	  96	  well	  plate.	  
After	  24	  hrs,	  media	  was	  aspirated	  and	  100µL	  of	  warmed	  MCF10A	  media	  
was	  added.	  After	  a	  further	  24	  hrs	  the	  plates	  were	  imaged	  using	  the	  
Automated	  Imaging	  BioApp	  on	  the	  Cytell	  Cell	  Imaging	  System	  (GE	  
Lifesciences).	  10	  fields	  at	  10x	  magnification	  in	  the	  GFP	  channel	  were	  
captured	  for	  each	  well.	  GFP	  expression	  confirms	  that	  the	  cell	  has	  
incorporated	  the	  shRNA	  into	  its	  genome	  and	  was	  expressing	  the	  shRNA	  
plasmid	  genes.	  
The	  images	  of	  either	  the	  1:63	  or	  the	  1:31	  final	  dilution	  were	  used	  to	  count	  
the	  GFP	  expressing	  cells	  as	  this	  range	  had	  50%	  of	  the	  cells	  expressing	  GFP,	  
which	  corresponds	  to	  only	  one	  transducing	  units/cell.	  Using	  the	  FIJI	  cell	  
	  1:3	  	  	  	  1:7	  	  	  	  1:15	  	  	  1:31	  	  	  1:63	  	  	  Control	  
MCF10A	  cells	  
96	  well	  plate	  
110µL	  each	  time	  
220µL	  of	  	  
harvested	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imaging	  software	  program’s	  cell	  counter	  plug-­‐in	  (National	  Institute	  of	  
Health)	  the	  quantity	  of	  cells	  expressing	  GFP	  were	  counted	  [70].	  To	  cause	  a	  
sufficient	  gene	  knockdown	  of	  PLK3	  in	  MCF10A	  cells,	  a	  multiplicity	  of	  
infection	  (MOI)	  of	  15	  was	  required,	  meaning	  15	  transducing	  units/seeded	  
cell,	  as	  previously	  determined	  in	  the	  lab	  by	  Tom	  Brew	  and	  James	  Frick.	  
The	  average	  count	  from	  the	  10	  fields	  was	  calculated	  and	  multiplied	  by	  
54.494	  to	  determine	  the	  TU/mL	  that	  was	  in	  the	  diluted	  100µL.	  The	  
transducing	  units/well	  was	  multiplied	  by	  the	  dilution	  and	  multiplied	  by	  10	  
to	  convert	  to	  TU/mL.	  The	  15	  transducing	  units/seeded	  cell	  required	  15,000	  
transducing	  units	  in	  50µL	  and	  was	  calculated	  using	  the	  density	  of	  the	  
seeded	  cells.	  
2.4 TRANSDUCTION	  
To	  test	  the	  synthetic	  lethal	  effect	  of	  a	  genetic	  knockdown	  of	  PLK3,	  the	  
shRNA	  created	  in	  Chapter	  2.3	  were	  transduced	  into	  MCF10A	  and	  CDH1-­‐/-­‐	  
cells.	  Their	  viability	  was	  measured	  by	  cell	  counting	  and	  the	  knockdown	  was	  
measured	  by	  RT-­‐qPCR.	  
2.4.1 CELL	  VIABILITY	  
1x104cells/well	  of	  MCF10A	  and	  1.5x104cells/well	  of	  CDH1-­‐/-­‐	  cells	  were	  
seeded	  in	  a	  96	  well	  plate	  in	  100µL	  of	  media	  and	  incubated	  at	  37°C.	  CDH1-­‐/-­‐	  
cells	  were	  seeded	  at	  a	  higher	  density	  to	  reach	  confluence	  at	  72	  hrs	  as	  it	  was	  
previously	  determined	  they	  take	  longer	  to	  adhere	  will	  have	  a	  parallel	  
growth	  rate	  to	  MCF10A	  cells.	  After	  24	  hrs	  the	  shRNA	  lentivirus	  was	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defrosted	  at	  room	  temperature	  and	  diluted	  in	  media.	  50µL	  of	  the	  lentivirus	  
containing	  15	  transducing	  units/seeded	  cell,	  was	  added	  to	  the	  100µL	  of	  
media	  and	  cells	  in	  appropriate	  wells.	  1-­‐3	  shRNA	  were	  tested	  each	  time,	  in	  
addition	  to	  cell	  only,	  non-­‐silencing	  and	  no	  insert	  controls.	  The	  non-­‐
silencing	  no	  insert	  and	  cell	  only	  acts	  as	  control	  to	  normalise	  any	  non-­‐
specific	  effects	  of	  shRNA	  transduction.	  	  	  
The	  cells	  on	  the	  outer	  wells	  were	  always	  excluded	  due	  to	  edge	  effects	  and	  
instead	  these	  wells	  were	  stained	  with	  1µg/mL	  of	  Hoechst	  33342	  at	  24	  hrs	  
as	  a	  quality	  control	  measure.	  Using	  the	  Cytell,	  stained	  cells	  were	  imaged	  at	  
4x	  magnification	  with	  four	  fields	  in	  the	  phase	  and	  DAPI	  channels.	  Images	  
were	  counted	  on	  Cell	  Profiler	  selecting	  the	  nuclei	  for	  each	  cell.	  Cell	  Profiler	  
is	  a	  software	  that	  allows	  large	  image	  sets	  to	  be	  processed	  over	  a	  wide	  range	  
of	  variable	  parameters	  that	  are	  able	  to	  specifically	  identify	  and	  count	  cells	  
[71].	  Counts	  were	  analysed	  to	  confirm	  that	  the	  plates	  were	  seeded	  evenly.	  
Plates	  with	  uneven	  seeding	  density	  were	  discontinued	  before	  introducing	  
the	  lentivirus.	  Once	  treated,	  cells	  were	  kept	  at	  37°C	  and	  5%	  CO2	  and	  
handled	  in	  accordance	  with	  viral	  containment	  conditions.	  
At	  24	  hrs	  post	  transduction,	  the	  media	  was	  changed	  by	  aspirating	  all	  150µL	  
from	  the	  wells	  and	  adding	  100µL	  of	  fresh	  complete	  MCF10A	  media	  with	  
1µg/mL	  puromycin.	  Puromycin	  selected	  for	  transduced	  cells	  as	  the	  pGIPZ	  
shRNA	  contained	  puromycin	  resistance.	  This	  was	  not	  be	  added	  to	  the	  cell	  
only	  wells	  as	  they	  do	  not	  express	  any	  resistance.	  Any	  cells	  not	  transduce	  
would	  die	  as	  a	  result	  of	  the	  puromycin.	  All	  remaining	  cells	  express	  shRNA	  
causing	  the	  knockdown	  of	  PLK3.	  This	  selection	  allowed	  the	  total	  cell	  count	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to	  accurately	  portray	  the	  differential	  effect	  on	  cell	  viability	  with	  and	  
without	  PLK3.	  
At	  72	  hrs	  post	  transduction	  all	  media	  was	  removed	  from	  the	  wells.	  Two	  
wells	  from	  each	  treatment	  group	  were	  used	  for	  RNA	  extraction	  (Chapter	  
2.4.2).	  	  The	  remaining	  wells	  were	  stained	  with	  1µg/mL	  of	  Hoechst	  33342	  
and	  0.5ug/mL	  propidium	  iodide	  in	  PBS	  for	  a	  minimum	  of	  half	  an	  hour	  and	  
imaged	  using	  the	  Cytell.	  Images	  from	  four	  fields	  at	  4x	  magnification	  were	  
taken	  using	  the	  Cytell’s	  Automated	  Imaging	  BioApp,	  or	  quantified	  came	  
directly	  by	  counting	  the	  cells	  from	  20	  fields	  at	  10x	  magnification	  using	  the	  
Viability	  or	  Cell	  Cycle	  BioApp.	  As	  a	  quality	  control	  Cell	  Profiler	  used	  the	  4x	  
images	  to	  also	  count	  the	  amount	  of	  cells	  [71].	  Results	  were	  analysed	  by	  
calculating	  the	  sum	  of	  the	  nuclei	  in	  each	  well.	  Technical	  replicates	  were	  
averaged	  for	  total	  cell	  count	  response	  to	  treatment.	  PLK3	  knockdown	  
samples	  were	  normalised	  to	  the	  non-­‐silencing	  treatment	  for	  each	  cell	  line,	  
to	  compare	  responses	  to	  treatment.	  
2.4.2 RNA	  EXTRACTION	  AND	  REVERSE	  TRANSCRIPTION	  
72	  hrs	  after	  transduction,	  two	  wells	  from	  each	  cell	  line	  treatment	  group	  
were	  examined	  to	  validate	  the	  knockdown	  efficiency	  using	  RT-­‐qPCR.	  Wells	  
were	  washed	  with	  PBS,	  and	  the	  RNAGEM	  Tissue	  PLUS	  kit	  (ZyGem)	  was	  used.	  
The	  amount	  of	  cells	  per	  well	  was	  ~5000	  and	  therefore	  a	  master	  mix	  with	  of	  
12.5µL	  of	  RNAGEM	  enzyme,	  62.5µL	  of	  SILVER	  buffer	  and	  925µL	  of	  MQ	  H2O	  
25µL	  mix	  was	  required.	  25µL	  of	  the	  mix	  was	  added	  to	  the	  40	  wells,	  
dislodged	  with	  a	  pipette	  tip,	  transferred	  to	  a	  PCR	  strip	  tube	  and	  heated	  to	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75°C	  in	  a	  ThermoCycler.	  This	  serves	  to	  activate	  the	  enzyme,	  ensures	  cell	  
lysis	  and	  the	  removes	  of	  RNAses	  by	  protein	  lysis.	  A	  second	  step	  with	  
DNAses	  in	  the	  ThermoCycler	  at	  37°C	  for	  5	  min	  followed	  by	  75°C	  for	  5	  min,	  
removed	  any	  DNA	  from	  the	  RNA	  extract.	  TE-­‐buffer	  was	  added	  so	  that	  the	  
pH	  was	  stable,	  serving	  to	  protect	  the	  RNA	  from	  degradation.	  
Reverse	  transcriptase	  (RT)	  was	  used	  to	  synthesize	  cDNA	  from	  the	  purified	  
RNA.	  The	  PrimeScript	  RT	  reagent	  Kit	  (TAKARA)	  was	  used	  to	  produce	  the	  
cDNA	  following	  the	  ‘SYBR	  Green	  assay	  protocol’.	  This	  involved	  creating	  
3.5µL/reaction	  of	  a	  combined	  buffer,	  RT	  enzyme,	  oligo	  dT	  Primer	  and	  
Random	  6	  mers.	  6.5µL	  of	  purified	  RNA	  was	  added	  to	  3.5µL	  of	  the	  mix	  
producing	  a	  final	  volume	  of	  10µL/reaction,	  which	  was	  incubated	  in	  the	  
ThermoCycler	  at	  37°C	  for	  15	  min	  (reverse	  transcription)	  and	  85°C	  for	  5	  sec	  
(enzyme	  inactivation).	  	  Two	  negative	  controls	  were	  also	  included,	  one	  
lacking	  the	  RT	  enzyme,	  the	  other	  lacking	  the	  template.	  
2.4.3 RT-­‐qPCR	  
The	  KAPA	  SYBR	  FAST	  RT-­‐qPCR	  Kit	  protocol	  (Kapa	  Biosystems)	  was	  used	  to	  
carry	  out	  RT-­‐qPCR	  of	  the	  cDNA	  and	  was	  the	  final	  process	  in	  determining	  
whether	  PLK3	  was	  successfully	  knocked	  down.	  
Housekeeping	  genes	  GAPDH	  and	  PPIA	  were	  used	  to	  normalise	  PLK3	  
expression.	  Primers	  were	  purchased	  from	  Integrated	  DNA	  Technologies	  
PLK3	  was	  designed	  using	  Primer3	  [72],	  GAPDH	  and	  PPIA	  were	  pre-­‐
designed	  (primer	  sequences	  in	  Appendix	  5.3).	  A	  1:6	  dilution	  of	  the	  cDNA	  
was	  used	  to	  negate	  any	  effects	  from	  residual	  reverse	  transcriptase.	  5µL	  of	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the	  cell	  only	  control	  cDNA	  from	  each	  cell	  line	  was	  used	  to	  create	  a	  series	  of	  
five	  four-­‐fold	  dilutions	  to	  calculate	  a	  standard	  curve	  and	  obtain	  the	  
efficiency	  of	  the	  RT-­‐qPCR	  reaction	  (Figure	  11).	  This	  enabled	  the	  use	  of	  the	  
Pfaffl	  method	  to	  analyse	  the	  results	  [73].	  	  
	  	   	  
Figure	   11	   –	  The	   1:4	   dilutions	   carried	   out	   for	   the	   standard	   curve	   of	   the	   RT-­‐
qPCR	  
Each	  sample	  was	  performed	  in	  duplicate	  in	  an	  8µL	  reaction.	  The	  8µL	  
consists	  of	  3.7µL	  of	  the	  1:6	  dilution	  of	  template	  cDNA,	  4µL	  of	  2xKAPA	  SYBR	  
FAST	  RT-­‐qPCR	  mix,	  0.12µL	  of	  forward	  and	  reverse	  primers	  (300nM),	  
0.16µL	  of	  50X	  ROX	  reference	  dye	  to	  normalise	  the	  signal,	  and	  0.02µL	  of	  MQ	  
H2O.	  This	  was	  carried	  out	  on	  a	  384-­‐well	  assay	  plate	  to	  accommodate	  for	  the	  
180	  reactions	  per	  experiment	  including	  negative	  no	  template	  controls	  of	  
MQ	  H2O.	  The	  RT-­‐qPCR	  was	  run	  in	  the	  ABI	  Prism	  7900HT	  with	  an	  enzyme	  
activation	  step	  of	  95°C	  for	  3	  min	  followed	  by	  40	  repeats	  of	  denaturation	  
95°C	  for	  15	  sec,	  annealing	  at	  57°C	  for	  15	  sec,	  and	  data	  acquisition	  at	  72°C	  
for	  15	  sec.	  The	  dissociation	  stage	  of	  95°C	  for	  15	  sec	  and	  60°C	  for	  15	  sec	  
1/6	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provided	  the	  final	  dissociation	  step	  and	  gave	  a	  melt	  curve	  to	  distinguish	  the	  
products	  of	  the	  reaction.	  
2.4.4 GEL	  AND	  SEQUENCE	  
To	  validate	  the	  RT-­‐qPCR	  primers	  and	  ensure	  we	  were	  testing	  the	  right	  
sequence,	  one	  of	  the	  products	  of	  the	  PLK3	  RT-­‐qPCR	  was	  analysed	  on	  a	  1.5%	  
agarose	  gel	  electrophoresis	  and	  another	  was	  also	  sent	  to	  University	  of	  
Otago	  DNA	  sequencing	  service.	  	  
The	  1.5%	  agarose	  gel	  was	  made	  using	  1x	  ethydium	  bromide	  and	  Tris	  
base,	  acetic	  acid	  and	  EDTA	  buffer	  solution.	  0.75g	  of	  agarose	  was	  added	  to	  
50mL	  of	  the	  buffer	  and	  microwaved	  till	  clear.	  The	  solution	  was	  poured	  into	  
a	  gel	  electrophoresis	  cast	  (LABREPCO)	  and	  left	  to	  set.	  The	  buffer	  was	  
poured	  around	  the	  gel	  and	  product	  was	  mixed	  in	  a	  4-­‐fold	  dilution	  with	  2x	  
bromophenol	  blue	  dye	  and	  loaded	  into	  the	  gels	  well	  alongside	  the	  Kapa	  
Universal	  ladder.	  The	  gel	  was	  run	  for	  30	  min	  at	  95	  volts.	  Images	  were	  taken	  
using	  the	  ChemiDoc	  MP	  System	  (Bio-­‐Rad).	  
To	  prepare	  for	  sequencing	  the	  potential	  93bp	  RT-­‐qPCR	  PLK3	  product,	  was	  
taken	  from	  the	  cell	  only	  well,	  as	  expression	  was	  higher	  in	  this	  treatment.	  
The	  product	  was	  cleaned	  up	  in	  a	  spin	  column	  by	  adding	  ethanol	  (EtOH)	  and	  
Sodium	  Acetate	  (NaAc)	  and	  washed	  out	  with	  40°C	  H2O.	  1µL	  of	  either	  the	  
forward	  or	  reverse	  PLK3	  primers	  was	  added	  to	  1µL	  of	  the	  cleaned	  RT-­‐qPCR	  
product	  and	  diluted	  with	  3µL	  of	  MQ	  H2O	  for	  each	  primer,	  according	  to	  the	  
Otago	  Genetic	  Analysis	  Sequencing	  Reaction	  Protocol.	  The	  results	  from	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their	  sequencing	  were	  analysed	  using	  SeqMonk	  (Babraham	  
Bioinformatics).	  
2.5 POLOXIPAN	  AND	  WORTMANNIN	  
To	  determine	  if	  current	  PLK3	  inhibitors	  caused	  synthetic	  lethality	  we	  used	  
poloxipan	  (Vitas-­‐M	  Laboratory)	  and	  wortmannin	  (Selleckchem)	  at	  a	  range	  
of	  concentrations	  to	  detect	  viability	  changes	  in	  MCF10A	  and	  CDH1-­‐/-­‐	  cells.	  
These	  inhibitors	  were	  diluted	  until	  soluble	  in	  a	  stock	  solution	  of	  DMSO.	  96-­‐
well	  black	  walled,	  clear	  bottom	  plates	  were	  seeded	  with	  4x104/well	  
MCF10A	  and	  CDH1-­‐/-­‐	  cells	  and	  incubated	  at	  37°C	  in	  an	  IncuCyte	  (Essen	  
Bioscience).	  The	  IncuCyte	  takes	  phase	  contrast	  images	  of	  three	  fields/well	  
at	  4x	  magnification	  every	  two	  hrs.	  Inbuilt	  software	  determines	  the	  cell	  
confluence	  over	  time,	  which	  correlates	  to	  their	  proliferation	  rate.	  
At	  24	  hrs,	  11µL	  of	  the	  PLK3	  protein	  inhibitor	  was	  applied	  to	  the	  cells	  from	  a	  
range	  of	  two	  fold	  dilutions	  in	  MCF10A	  complete	  media	  (controls	  equivalent	  
to	  the	  concentration	  of	  DMSO	  in	  the	  highest	  dosage	  of	  the	  inhibitor	  were	  
included).	  Poloxipan	  was	  optimized	  to	  range	  from	  final	  concentrations	  of	  
0.25µM	  –	  4µM.	  Wortmannin	  was	  optimised	  to	  range	  from	  0.625µM	  –	  10µM.	  
After	  treatment	  the	  plates	  were	  returned	  to	  the	  IncuCyte	  for	  a	  further	  48	  
hrs.	  	  
48	  hrs	  post	  treatment	  the	  cells	  were	  stained	  with	  1µg/mL	  Hoechst	  33342	  
and	  0.5µg/mL	  propidium	  iodide	  and	  imaged	  on	  the	  Cytell	  or	  the	  Cytation	  
Cell	  Imaging	  Multimode	  Reader	  (BioTek).	  The	  same	  parameters	  were	  used	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in	  imaging	  the	  shRNA	  treatments	  nuclei	  on	  the	  Cytell	  BioApps	  (Chapter	  
2.4.1).	  Hoechst	  nuclei	  staining	  and	  imaging	  from	  the	  Cytation	  gave	  an	  
accurate	  total	  cell	  count	  from	  fluorescent	  imaging	  of	  six	  fields	  at	  4x	  
magnification.	  Cell	  count	  was	  confirmed	  by	  analysing	  the	  same	  images	  on	  
Cell	  Profiler.	  Comparing	  the	  treatments	  after	  normalising	  to	  the	  DMSO	  
controls	  for	  each	  cell	  line	  formed	  the	  difference	  in	  viability	  between	  various	  
concentrations	  of	  the	  inhibitor	  between	  each	  cell	  line.	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3  RESULTS	  
“Somewhere,	  something	  incredible	  is	  waiting	  to	  be	  known.”	  –	  Carl	  Sagan	  
The	  recent	  genome-­‐wide	  siRNA	  screen	  conducted	  in	  our	  lab	  identified	  
PLK3	  as	  a	  putative	  synthetic	  lethal	  candidate	  of	  CDH1-­‐/-­‐	  cells	  [27].	  This	  
screen	  observed	  that	  PLK3	  knockdown	  caused	  a	  significant	  yet	  selective	  
inhibition	  to	  growth	  in	  CDH1-­‐/-­‐	  cells	  compared	  to	  MCF10A	  cells.	  The	  screen	  
resulted	  in	  a	  viability	  ratio	  of	  0.84	  calculated	  from	  the	  CDH1-­‐/-­‐	  cells	  having	  a	  
viability	  of	  76%	  compared	  to	  a	  viability	  of	  90%	  in	  the	  MCF10A	  cells.	  The	  
aim	  in	  this	  study	  was	  to	  validate	  the	  synthetic	  lethal	  interaction	  between	  
CDH1-­‐/-­‐	  and	  PLK3,	  to	  provide	  further	  evidence	  of	  PLK3	  as	  a	  potential	  target	  
for	  HDGC	  preventative	  treatment.	  This	  was	  achieved	  by	  knocking	  down	  the	  
expression	  of	  PLK3	  mRNA	  using	  shRNA	  and	  using	  PLK3	  inhibitors	  
poloxipan	  and	  wortmannin.	  
In	  the	  shRNA	  knockdown	  of	  PLK3,	  two	  shRNA	  were	  successful.	  A	  synthetic	  
lethal	  trend	  was	  observed	  in	  one	  and	  not	  in	  the	  other.	  The	  synthetic	  lethal	  
relationship	  was	  not	  greater	  than	  the	  viability	  ratio	  threshold	  of	  0.85	  set	  at	  
the	  siRNA	  high	  throughput	  screen.	  The	  p-­‐values	  distinguishing	  the	  
difference	  between	  MCF10A	  and	  CDH1-­‐/-­‐	  after	  PLK3	  knockdown	  from	  both	  
shRNA	  were	  not	  significant.	  The	  treatment	  of	  poloxipan	  and	  wortmannin	  
targeting	  PLK3	  did	  not	  reveal	  a	  significant	  synthetic	  lethal	  phenotype.	  This	  
indicates	  that	  PLK3	  and	  CDH1	  do	  not	  have	  a	  true	  significant	  lethal	  
relationship.	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3.1 PLK3	  SHRNA	  
Seven	  different	  shRNA	  plasmids	  (Dharmacon)	  targeting	  PLK3	  were	  used	  
for	  the	  knockdown	  experiments.	  The	  shRNA	  plasmids	  were	  propagated	  in	  
overnight	  cultures,	  extracted	  and	  quantified	  before	  viral	  packaging.	  The	  
shRNA	  plasmids	  were	  transfected	  alongside	  psPAX2	  and	  VSVG	  in	  293FT	  
cells	  to	  produce	  the	  PLK3	  targeting	  virus	  (Chapter	  2.3).	  A	  viral	  titre	  
determined	  if	  there	  is	  subsequent	  quantity	  of	  virus	  to	  proceed	  with	  
transduction	  and	  RT-­‐qPCR	  determined	  whether	  the	  viability	  reflects	  a	  true	  
knockdown	  of	  PLK3.	  
3.1.1 VIRAL	  TITRE	  YIELD	  
The	  required	  viral	  titre	  needed	  to	  exceed	  4.5x105	  TU/mL	  in	  order	  to	  
achieve	  a	  MOI	  of	  15	  viral	  particles/seeded	  cell.	  All	  transfections	  produced	  
sufficient	  concentrations	  except	  for	  the	  shRNA	  identified	  as	  E12	  and	  this	  
was	  not	  used	  for	  transductions	  (Table	  6).	  
Table	  6	   -­‐	  The	  titre	  of	   the	  shRNA	  and	  the	  number	  of	   transductions	   that	  were	  
conducted	  from	  each	  virus.	  
shRNA	  ID	   Target	   Titre	  (TU/mL)	   The	  Number	  of	  Transductions	  Conducted	  
E4	   PLK3	   5.9x105	   5	  
E5	   PLK3	   7.9x105	   2	  
E6	   PLK3	   7.4x105	   1	  
E7	   PLK3	   8.3x105,	  1.5x106	   9	  
E11	   PLK3	   5.4x105	   5	  
E12	   PLK3	   1.7x105	   0	  
F1	   PLK3	   4.9x105	   4	  
NS	   -­‐	   1.1x106	   Control	  (used	  in	  all)	  
NI	   -­‐	   2.98x106	   Control	  (used	  in	  all)	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3.1.2 POST	  TRANSDUCTION	  VIABILITY	  
MCF10A	  and	  CDH1-­‐/-­‐	  cells	  were	  seeded	  in	  a	  96	  well	  plate	  and	  transduced	  
with	  one	  of	  the	  six	  shRNA	  viruses.	  Included	  in	  every	  biological	  repeat	  were	  
cell	  only,	  no	  insert	  shRNA	  and	  non-­‐silencing	  shRNA	  controls.	  Puromycin	  
selected	  for	  the	  cells	  that	  were	  transduced	  by	  the	  virus.	  After	  72	  hrs	  post	  
transduction	  of	  the	  virus,	  cells	  were	  stained	  and	  imaged	  In	  the	  Cytell.	  This	  
provided	  a	  total	  cell	  count	  in	  each	  well	  with	  4	  technical	  repeats	  for	  each	  
treatment.	  Viability	  of	  the	  treatment	  was	  determined	  by	  normalising	  each	  
treatments	  average	  total	  cell	  count	  to	  the	  equivalent	  average	  total	  cell	  
count	  of	  the	  non-­‐silencing	  control	  for	  each	  cell	  line.	  A	  normalised	  value	  of	  1	  
correlates	  to	  no	  effect,	  if	  the	  normalised	  viability	  was	  <1	  it	  was	  lethal.	  If	  >1	  
the	  treatment	  promoted	  growth	  and	  was	  not	  lethal.	  Viabilities	  from	  
MCF10A	  and	  CDH1-­‐/-­‐	  cells	  were	  compared	  to	  calculate	  the	  viability	  ratio	  
which	  is	  considered	  synthetic	  lethal	  if	  ≥0.85.	  
26	  knockdowns	  were	  conducted	  using	  the	  six	  different	  shRNA	  sequences	  
(Table	  6).	  From	  the	  26	  knockdowns,	  ten	  were	  excluded	  due	  to	  suboptimal	  
consistency	  in	  seeding	  density	  leaving	  the	  results	  of	  only	  four	  shRNA.	  
Primary	  results	  trended	  towards	  a	  synthetic	  lethal	  response	  due	  to	  
decreased	  viability	  in	  CDH1-­‐/-­‐	  cells	  compared	  to	  MCF10A	  cells.	  Each	  
individual	  shRNA	  had	  variable	  viability	  responses	  between	  the	  cell	  lines	  as	  
the	  viability	  ratio	  was	  not	  always	  synthetic	  lethal	  (Table	  7	  and	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Figure	  12).	  The	  greatest	  synthetic	  lethal	  response	  was	  seen	  in	  response	  to	  
the	  knockdown	  from	  shRNA	  E7	  (n=7)	  with	  a	  viability	  ratio	  of	  0.75.	  The	  E11	  
shRNA	  treatment	  (n=3)	  did	  not	  produce	  a	  synthetic	  lethal	  response.	  E5	  had	  
one	  biological	  repeat	  which	  was	  synthetic	  lethal,	  and	  E4	  had	  no	  effect	  
considering	  the	  insignificant	  p-­‐value.	  To	  validate	  the	  true	  relationship	  
between	  PLK3	  and	  CDH1,	  the	  PLK3	  knockdown	  needed	  confirmation	  by	  
determining	  the	  expression	  level	  of	  PLK3	  derived	  from	  RT-­‐qPCR.	  
Table	   7	   -­‐	   Average	   effect	   of	   the	   attempted	   PLK3	   shRNA	   knockdown	   on	  
MCF10A	  and	  CDH1-­‐/-­‐	  cell	  viability.	  






E4	   1.01	   0.98	   0.98	   0.72	  
E5	   1.20	   0.99	   0.82	   -­‐	  
E7	   1.04	   0.78	   0.75	   0.08	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Figure	  12	  –	  Average	  of	   the	  normalised	  viability	  of	  MCF10A	  and	  CDH1-­‐/-­‐	   cells	  
after	   shRNA	   treatment.	  Cells	  were	   transduced	  with	  shRNA,	   stained	  and	   imaged	  
to	  determine	  a	  total	  cell	  count.	  Viability	  was	  determined	  by	  normalising	  the	  total	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3.1.3 PLK3	  KNOCKDOWN	  EFFICIENCY.	  
The	  cell	  viability	  study	  needed	  confirmation	  that	  PLK3	  had	  been	  knocked	  
down	  by	  the	  lentiviral	  constructs.	  The	  expression	  of	  PLK3	  was	  analysed	  
using	  the	  Pfaffl	  method	  [73].	  The	  Pfaffl	  method	  uses	  the	  efficiency	  of	  the	  
reaction	  derived	  from	  the	  slope	  of	  the	  standard,	  in	  an	  equation	  with	  the	  
cycle	  threshold	  (Ct)	  of	  the	  control	  and	  the	  Ct	  of	  the	  sample/treatment	  the	  
expression	  is	  being	  calculated	  for.	  This	  value	  from	  the	  PLK3	  knockdown	  is	  
normalised	  to	  the	  average	  of	  the	  values	  of	  the	  two	  housekeeping	  genes	  
GAPDH	  and	  PPIA.	  Two	  technical	  repeats	  of	  each	  genes	  expression	  from	  the	  
PLK3	  knockdown	  are	  averaged	  and	  normalised	  to	  the	  non-­‐silencing	  
controls	  within	  that	  cell	  line.	  
To	  confirm	  that	  the	  RT-­‐qPCR	  was	  actually	  measuring	  the	  expression	  of	  the	  
PLK3,	  GAPDH,	  and	  PPIA,	  the	  products	  of	  the	  reaction	  were	  ran	  on	  a	  gel	  and	  
sent	  for	  sequencing.	  The	  RT-­‐qPCR	  products	  were	  separated	  by	  size	  through	  
electrophoresis	  on	  a	  1.2%	  agarose	  gel.	  In	  comparison	  with	  the	  Kapa	  
Universal	  ladder	  the	  size	  of	  the	  PLK3	  product	  was	  around	  100bp.	  This	  
indicated	  that	  our	  product	  from	  the	  RT-­‐qPCR	  was	  PLK3	  as	  the	  primers	  
were	  designed	  to	  produce	  a	  93bp	  product.	  PPIA	  primers	  produced	  the	  
expected	  138bp	  product	  but	  it	  also	  very	  small	  amounts	  of	  a	  450bp	  product.	  
The	  larger	  product	  is	  indicative	  of	  contamination.	  The	  GAPDH	  primers	  
produced	  a	  band	  at	  the	  expected	  size	  of	  200bp	  (Figure	  13).	  	  
The	  PLK3	  product	  was	  also	  confirmed	  by	  sequencing	  the	  reactions	  product.	  
To	  prepare	  the	  RT-­‐qPCR	  PLK3	  product	  for	  sequencing,	  the	  product	  was	  
cleaned	  in	  a	  ethanol	  spin	  column	  wash	  and	  diluted	  in	  MQ	  H2O	  with	  either	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the	  forward	  or	  revers	  primer	  it	  was	  sequenced	  with.	  The	  sequences	  of	  both	  
the	  forward	  and	  reverse	  reactions	  was	  a	  match	  with	  the	  expected	  sequence	  
in	  the	  PLK3	  gene.	  This	  confirmed	  that	  the	  RT-­‐qPCR	  was	  testing	  for	  PLK3	  
expression.	  
	  
Figure	   13	   -­‐	   Agarose	   gel	   containing	   the	   products	   of	   the	   RT-­‐qPCR	   reaction.	  
Lanes	   are	   as	   follows:	   1	   =	   ladder,	   2	   =	  PLK3	   from	   cell	   only	   (CO)	   control,	   3	   =	  PLK3	  
from	  E4	  shRNA	  treatment	   (E4),	  4	  =	  no	   template	   (NT)	  H2O	  control,	  5	  =	  PPIA	   from	  
CO	  6	  =	  PPIA	   from	  E4,	  7	  =	  GAPDH	   from	  CO.	  8	  =	  GAPDH	   from	  E$	  All	  products	  were	  
from	  MCF10A	  cells.	  
The	  expression	  of	  PLK3	  from	  the	  non-­‐silencing	  controls	  did	  not	  undergo	  
any	  knockdown	  and	  were	  considered	  as	  having	  normal	  expression.	  A	  
normalised	  value	  of	  1	  correlated	  to	  no	  knockdown,	  >1	  would	  mean	  the	  
treatment	  had	  more	  PLK3	  than	  the	  control	  and	  <1	  would	  mean	  there	  was	  
less	  PLK3.	  A	  knockdown	  was	  considered	  successful	  if	  the	  level	  of	  PLK3	  was	  
<0.5	  (Figure	  14).	  	  
There	  were	  five	  transductions	  that	  were	  successful	  in	  knocking	  down	  PLK3	  
expression	  in	  both	  cell	  lines	  at	  the	  same	  time.	  Two	  were	  from	  E4,	  one	  from	  
PLK3 NT PPIA GAPDH 
	   	   	   












	   65	  
E5	  and	  three	  from	  E7.	  The	  11	  remaining	  transductions	  were	  only	  
successful	  in	  knocking	  down	  PLK3	  in	  one	  or	  neither	  of	  the	  MCF10A	  or	  
CDH1-­‐/-­‐	  cell	  lines.	  All	  repeats	  of	  E11	  shRNA	  were	  unsuccessful	  in	  knocking	  
down	  PLK3	  expression	  in	  both.	  These	  11	  unsuccessful	  knockdowns	  were	  
withdrawn	  from	  comparison	  (Figure	  15).	  
	  
Figure	   14	   –	   Average	   of	   the	   normalised	   expression	   of	   PLK3	   in	   MCF10A	   and	  
CDH1-­‐/-­‐	   cells	   from	   every	   transduction.	   Values	   were	   normalised	   to	   the	   non-­‐
silencing	  control.	  A	  normalised	  value	  <0.5	   is	  a	  successful	  knockdown	  as	   it	  means	  
the	   expression	   was	   halved.	   The	   amount	   of	   biological	   repeats	   were:	   E4	   n=5,	   E5	  
n=1,	  E7	  n=8	  and	  E11	  n=2.	  
	  
Figure	   15	   -­‐	  Average	   of	   the	   normalised	   expression	   of	   PLK3	   in	   MCF10A	   and	  
CDH1-­‐/-­‐	   cells	   for	   the	   successful	   knockdowns.	   The	   normalised	   value	   of	   PLK3	  

























































	   66	  
Expression	   values	  were	   normalised	   to	   the	   non-­‐silencing	   control.	   The	   amount	   of	  
biological	  repeats	  were:	  E4	  n=2,	  E5	  n=1	  and	  E7	  n=3.	  
The	  average	  viability	  of	  a	  successful	  E4	  PLK3	  knockdown	  did	  not	  meet	  the	  
hypothesis	  because	  it	  caused	  a	  reverse	  synthetic	  lethal	  effect.	  The	  reverse	  
synthetic	  lethal	  effect	  is	  a	  lower	  viability	  in	  the	  MCF10A	  cells	  compared	  to	  
the	  CDH1-­‐/-­‐	  cells.	  A	  successful	  knockdown	  with	  E7	  shRNA	  was	  consistent	  
with	  the	  hypothesis	  as	  it	  shows	  a	  synthetic	  lethal	  effect	  (Table	  8	  and	  Figure	  
16).	  The	  p-­‐value	  of	  both	  these	  results	  are	  not	  significant	  and	  therefore	  they	  
indicate	  the	  null	  hypothesis	  should	  be	  accepted,	  meaning	  that	  there	  is	  no	  
conclusive	  evidence	  of	  a	  either	  a	  synthetic	  lethal	  relationship	  or	  reverse	  
synthetic	  lethal	  relationship	  between	  PLK3	  and	  CDH1	  (Table	  1).	  
Table	   8	   -­‐	   Viability	   of	   the	   MCF10A	   and	   CDH1-­‐/-­‐	   cells	   after	   successful	   PLK3	  
knockdown	   The	   viability	   is	   analysed	   with	   standard	   error	   (STD	   Error),	   p-­‐value	  
and	  viability	  ratio.	  A	  viability	  ratio	  ≤0.85	  is	  considered	  synthetic	  lethal.	  
Viability	  of	  Successful	  PLK3	  Knockdowns	  
shRNA	  




Value	  Viability	   STD	  Error	   Viability	   STD	  Error	  
E4	   0.69	   0.26	   1.14	   0.17	   1.65	   0.18	  
E7	   0.9	   0.12	   0.83	   0.03	   0.92	   0.60	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Figure	  16	  –	  Average	  of	   the	  normalised	  viability	   in	  MCF10A	  and	  CDH1-­‐/-­‐	   cells	  
after	   successful	   PLK3	   shRNA	   knockdowns.	   The	   amount	   of	   biological	   repeats	  
were:	   E4	   n=2	   and	   E7	   n=3.	   Dividing	   the	   average	   total	   cell	   count	   from	   the	  
treatment	  by	   the	   average	   total	   cell	   count	   from	   the	  non-­‐silencing	   control	   created	  
normalised	  values.	  
3.2 POLOXIPAN	  
MCF10A	  and	  CDH1-­‐/-­‐	  cells	  were	  seeded	  in	  a	  96	  well	  plate	  and	  their	  
confluence	  was	  imaged	  and	  measured	  using	  the	  IncuCyte.	  The	  images	  show	  
the	  behaviour	  of	  the	  cells	  before	  and	  after	  treatment	  of	  poloxipan.	  Cells	  
were	  treated	  with	  poloxipan	  24	  hrs	  after	  seeding,	  and	  stained	  and	  imaged	  
to	  count	  the	  nuclei	  at	  48	  hrs.	  The	  total	  cell	  count	  provided	  determination	  of	  
viability.	  
Poloxipan	  is	  a	  pan	  inhibitor	  of	  the	  polo-­‐like	  kinase	  family.	  It	  is	  currently	  the	  
most	  active	  PLK3	  inhibitor	  with	  an	  IC50	  of	  3.0µM	  but	  it	  also	  inhibits	  PLK1	  at	  
3.2µM.	  The	  concentrations	  we	  used	  were	  0.25µM,	  0.5µM,	  1.0µM,	  2.0µM,	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3.2.1 GROWTH	  OF	  POLOXIPAN	  TREATED	  CELLS	  
The	  confluence	  from	  the	  IncuCyte	  showed	  that	  a	  range	  of	  concentrations	  of	  
poloxipan	  did	  little	  to	  change	  the	  growth	  over	  time	  of	  the	  MCF10A	  cells	  
(Figure	  17).	  The	  CDH1-­‐/-­‐	  cells	  responded	  to	  poloxipan	  treatment	  with	  a	  
reduction	  of	  confluence	  after	  being	  treated.	  The	  CDH1-­‐/-­‐	  cells	  were	  able	  to	  
recover	  and	  continue	  growing.	  	  
The	  images	  for	  the	  IncuCyte	  (Figure	  18)	  show	  poloxipan	  would	  only	  stall	  
the	  growth	  of	  MCF10A	  cells	  at	  the	  first	  2	  hrs,	  were	  as	  CDH1-­‐/-­‐	  cells	  actually	  
regress.	  Any	  migrating	  CDH1-­‐/-­‐	  cells	  at	  the	  time	  of	  treatment	  retract	  and	  
isolated	  cells	  associated	  together	  forming	  a	  tight	  rounded	  clumps.	  Images	  
of	  the	  MCF10A	  cells	  showed	  little	  response	  to	  Poloxipan	  over	  the	  treatment	  
period	  that	  indicates	  a	  high	  viability.	  In	  contrast,	  CDH1-­‐/-­‐	  cells	  clearly	  had	  
growth	  inhibition.	  Quantifying	  the	  viability	  from	  the	  normalising	  the	  total	  
cell	  count	  provided	  the	  further	  specification	  as	  to	  whether	  the	  treatment	  
left	  the	  cells	  viable.	   	  




Figure	   17	   -­‐	   Pre	   and	   post	   treatment	   confluence	   over	   time	   of	   MCF10A	   and	  
CDH1-­‐/-­‐	   cells	   treated	  with	  4µM	  of	  poloxipan	  Cells	  had	  from	  3	  technical	  repeats	  
with	   confluence	   recorded	   every	   2	   hrs.	   Cells	   were	   treated	   with	   poloxipan	   after	  
time	   0	  with	   a	   range	   of	   concentrations	   of	   which	   the	   lowest	   and	   highest	   (0.25µM	  
and	  0.4µM)	  are	  shown	  alongside	  the	  DMSO	  control.	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MCF10A	  
-­‐2	  hrs	   0	  hrs	   2	  hrs	  
	  
	  
4	  hrs	   6	  hrs	   12	  hrs	  
	  
CDH1-­‐/-­‐	  
-­‐2	  hrs	   0	  hrs	   2	  hrs	  
	  
4	  hrs	   6	  hrs	   12	  hrs	  
Figure	  18	  -­‐	  Pre	  and	  post	  treatment	  images	  MCF10A	  and	  CDH1-­‐/-­‐	  cells	  treated	  
with	   4μM	   of	   poloxipan.	   Images	   shown	   of	   MCF10A	   cells	   were	   all	   from	  well	   C3,	  
field	  2;	   Images	  of	  CDH1-­‐/-­‐	   cells	  were	  all	   from	  well	   F3,	   field	  3.	   Images	  were	   taken	  
every	   2	   hrs,	   of	   which	   the	   -­‐2,	   0,	   2,	   4,	   6,	   and	   12-­‐hour	   time	   points	   are	   shown.	  
Treatment	  was	  administered	  after	  time	  0.	  First	  response	  is	  seen	  at	  2	  hrs.	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3.2.2 VIABILITY	  OF	  POLOXIPAN	  TREATED	  CELLS	  
The	  viability	  of	  four	  biological	  repeats	  gave	  conclusive	  results	  that	  PLK3	  
inhibition	  by	  poloxipan	  was	  not	  synthetic	  lethal	  to	  CDH1-­‐/-­‐	  cells.	  48	  hrs	  
after	  poloxipan	  was	  administered	  the	  cell	  count	  was	  analysed	  by	  staining	  
the	  cells,	  and	  analysed	  from	  the	  images	  taken	  using	  the	  Cytation	  and	  Cell	  
Profiler.	  The	  cell	  count	  for	  each	  poloxipan	  treatment	  was	  normalised	  to	  the	  
equivalent	  DMSO	  control	  of	  that	  cell	  type.	  The	  viability	  ratio	  was	  
determined	  from	  the	  normalised	  viability	  of	  MCF10A	  and	  CDH1-­‐/-­‐	  cell	  lines	  
(Table	  9	  and	  Figure	  19).	  A	  treatment	  causing	  a	  viability	  ratio	  ≤0.85	  is	  
synthetic	  lethal,	  while	  a	  treatment	  causing	  a	  viability	  ratio	  >1	  is	  having	  a	  
reverse	  synthetic	  lethal	  effect.	  A	  reverse	  synthetic	  lethal	  treatment	  (when	  
the	  MCF10A	  cells	  have	  a	  lower	  viability	  after	  treatment	  than	  the	  CDH1-­‐/-­‐	  
cells)	  was	  observed	  at	  0.25µM,	  0.5µM	  and	  1µM	  concentrations	  of	  
poloxipan.	  The	  0.25µM	  and	  1µM	  treatments	  were	  also	  significant	  (n=4).	  	  
Poloxipan	  did	  have	  a	  dose	  dependent	  effect	  that	  at	  the	  highest	  
concentration	  (4.0µM)	  was	  sufficient	  to	  lower	  the	  MCF10A	  viability	  to	  a	  
normalised	  value	  of	  0.63	  in	  the	  MCF10A	  cells.	  A	  further	  increase	  in	  the	  
concentration	  of	  Poloxipan	  would	  have	  reduced	  the	  viability	  to	  a	  
normalised	  value	  of	  <0.50.	  
The	  CDH1-­‐/-­‐	  cells	  treated	  with	  2µM	  and	  4µM	  concentrations	  of	  poloxipan	  
showed	  that	  the	  CDH1-­‐/-­‐	  cells	  were	  less	  viable	  than	  the	  MCF10A	  cells.	  The	  
synthetic	  lethal	  viability	  ratio	  was	  not	  met	  and	  therefore	  the	  inhibition	  of	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PLK3	  with	  poloxipan	  in	  CDH1-­‐/-­‐	  cells	  is	  not	  synthetic	  lethal.	  The	  p-­‐values	  
also	  indicate	  that	  this	  was	  not	  a	  significant	  effect	  (n=4)	  (Table	  9).	  
Table	   9	   –	   Average	   Viability	   of	   MCF10A	   and	   CDH1-­‐/-­‐	   cells	   to	   poloxipan	  
treatment	  normalised	   to	   the	  DMSO	  control.	  The	  standard	  error	  (STD	  Error)	  of	  
the	   viability;	   the	   viability	   ratio;	   and	   the	  p-­‐values	  of	   the	  poloxipan	   treatment	   are	  
also	  indicated.	  
Poloxipan	  Treatment	  
	   MCF10A	   CDH1
-­‐/-­‐	  
Viability	  
Ratio	   P-­‐Value	  
	   Viability	  
STD	  
Error	   Viability	  
STD	  
Error	  
0.25µM	   0.95	   0.04	   1.10	   0.07	   1.16	   0.02	  
0.5µM	   1.01	   0.03	   1.10	   0.09	   1.10	   0.16	  
1.0µM	   0.92	   0.02	   1.09	   0.04	   1.08	   0.00	  
2.0µM	   0.97	   0.12	   0.91	   0.08	   0.94	   0.08	  
4.0µM	   0.63	   0.22	   0.61	   0.14	   0.97	   0.43	  
	  
Figure	  19	  -­‐	  Average	  of	  the	  normalised	  viability	  of	  MCF10A	  and	  CDH1-­‐/-­‐	  cells	  
after	  treatment	  with	  poloxipan.	  Poloxipan	  treatment	  was	  in	  0.25µM,	  0.5µM,	  
1.0µM,	  2.0µM	  and	  4.0µM	  concentrations.	  Four	  biological	  repeats	  each	  with	  six	  
technical	  repeats.	  Cells	  were	  treated	  24	  hrs	  after	  seeding	  and	  viability	  measured	  
from	  total	  cell	  count	  at	  48	  hrs	  after	  treatment.	  Total	  cell	  count	  was	  normalised	  to	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3.3 WORTMANNIN	  
In	  the	  same	  pattern	  as	  poloxipan	  (Chapter	  2.5),	  wortmannin	  was	  
administered	  to	  the	  MCF10A	  and	  CDH1-­‐/-­‐	  cells	  and	  imaged	  in	  the	  IncuCyte	  
to	  measure	  confluence	  changes	  over	  time.	  The	  images	  show	  the	  behaviour	  
of	  the	  cells	  before	  and	  after	  treatment	  of	  poloxipan.	  Cells	  were	  treated	  24	  
hrs	  after	  seeding,	  and	  stained	  and	  imaged	  to	  count	  the	  nuclei	  at	  48	  hrs.	  The	  
total	  cell	  count	  was	  normalised	  to	  the	  DMSO	  control	  for	  determination	  of	  
cell	  viability	  in	  response	  to	  treatment.	  
Wortmannin	  is	  a	  PI3K	  inhibitor	  with	  and	  IC50	  value	  of	  3.0nM	  that	  also	  
inhibits	  PLK3.	  It	  has	  been	  well	  characterised	  and	  used	  in	  many	  in	  vitro	  and	  
in	  vivo	  studies.	  Different	  isoforms	  are	  in	  clinical	  trials	  for	  those	  who	  have	  
PI3K	  driven	  tumours.	  Wortmannin	  is	  treated	  at	  concentrations	  at	  which	  it	  
is	  known	  to	  inhibit	  PLK3	  and	  PLK1.	  The	  IC50	  values	  of	  wortmannin	  for	  
PLK3	  are	  48nM	  and	  5.8nM	  for	  PLK1.	  Our	  experiment	  optimised	  
wortmannin	  to	  be	  treated	  at	  0.63µM,	  1.25µM,	  2.5µM,	  5.0µM,	  and	  10.0µM.	  
3.3.1 GROWTH	  OF	  WORTMANNIN	  TREATED	  CELLS	  
Wortmannin	  caused	  a	  significant	  growth	  inhibition	  and	  a	  decrease	  in	  cell	  
confluence	  within	  the	  first	  2	  hrs	  of	  treatment.	  The	  effect	  of	  wortmannin	  had	  
a	  dose-­‐dependent	  relationship	  (Figure	  20).	  The	  cells	  treated	  with	  a	  lower	  
concentration	  of	  wortmannin	  recovered	  to	  the	  normal	  growth	  rate	  
observed	  in	  the	  DMSO	  control,	  quicker	  than	  cells	  treated	  at	  a	  higher	  dose.	  
Wortmannin	  affected	  both	  MCF10A	  and	  CDH1-­‐/-­‐,	  but	  CDH1-­‐/-­‐	  had	  a	  greater	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Figure	   20	   –	   Pre	   and	   post	   treatment	   confluence	   over	   time	   of	   MCF10A	   and	  
CDH1-­‐/-­‐	   cells	   treated	   with	   10µM	   of	   wortmannin	   After	   time	   0,	   cells	   were	  
treated	   with	   a	   range	   of	   concentrations	   of	   Wortmannin	   of	   which	   0.625µM	   and	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MCF10A	  
	   -­‐2	  hrs	   0	  hrs	   2	  hrs	   4	  hrs	  
	  
	   8	  hrs	   16	  hrs	   20	  hrs	   24	  hrs	  
CDH1-­‐/-­‐	  
	   -­‐2	  hrs	   0	  hrs	   2	  hrs	   4	  hrs	  
	  
	  
	   8	  hrs	   16	  hrs	   20	  hrs	   24	  hrs	  
Figure	   21	   -­‐	   Images	   of	   the	   MCF10A	   and	   CDH1-­‐/-­‐	   cells	   before	   and	   after	  
treatment	   of	   10μM	   of	   wortmannin.	   The	   MCF10A	   images	   were	   from	   well	   B11	  
and	  the	  1st	  field	  of	  view.	  The	  CDH1-­‐/-­‐	  images	  were	  from	  well	  E11,	  and	  the	  3rd	  field	  
of	  view.	  Images	  were	  taken	  in	  the	  IncuCyte	  every	  2	  hrs	  of	  which	  the	  -­‐2,	  0,	  4,	  8,16,	  
20,	  and	  24	  hour	  time	  points	  are	  shown.	  Treatment	  of	  Wortmannin	  occurred	  after	  
the	  0	  hrs,	  the	  first	  response	  is	  seen	  at	  2	  hrs.	  
	   76	  
The	  images	  obtained	  from	  the	  IncuCyte	  (Figure	  21)	  showed	  that	  
wortmannin	  treatment	  rendered	  the	  migrating	  and	  isolated	  MCF10A	  and	  
CDH1-­‐/-­‐	  cells	  unable	  to	  grow.	  CDH1-­‐/-­‐	  cells	  clumped	  together	  and	  existing	  
clumps	  were	  reduced	  in	  size.	  After	  16	  hrs	  CDH1-­‐/-­‐	  cells	  were	  again	  growing.	  
There	  clumped	  MCF10A	  cells	  that	  had	  no	  immediate	  effect	  in	  the	  first	  4	  hrs.	  
The	  lack	  of	  growth	  is	  more	  evident	  in	  the	  CDH1-­‐/-­‐	  cells	  and	  indicates	  that	  
wortmannin	  treatment	  is	  lethal	  to	  	  
3.3.2 VIABILITY	  OF	  WORTMANNIN	  TREATED	  CELLS	  
48	  hrs	  after	  the	  wortmannin	  treatment,	  cells	  were	  imaged	  in	  the	  Cytation	  
to	  calculate	  the	  total	  cell	  count.	  The	  cell	  count	  of	  each	  treatment	  was	  
normalised	  to	  the	  equivalent	  DMSO	  of	  that	  cell	  line,	  which	  provided	  the	  
viability	  as	  conducted	  I’,	  meaning	  we	  must	  accept	  the	  null	  hypothesis.	  We	  
can	  conclude	  that	  there	  is	  no	  collaborating	  significant	  synthetic	  lethal	  
relationship	  or	  reverse	  synthetic	  lethal	  relationship	  between	  wortmannin	  
and	  CDH1-­‐/-­‐	  cells.	  
Table	  10	   –	  Average	  Viability	   of	  MCF10A	  and	  CDH1-­‐/-­‐	   cells	   after	  wortmannin	  
treatment,	  normalised	  to	  the	  DMSO	  control.	  The	  standard	  error	  (STD	  Error)	  of	  
the	  viability;	  the	  viability	  ratio;	  and	  p-­‐values	  of	  the	  wortmannin	  treatment.	  
Wortmannin	  Treatment	  
	  	   MCF10A	   CDH1-­‐/-­‐	  
Viability	  
Ratio	   P-­‐Value	  	  	   Viability	   STD	  Error	   Viability	  
STD	  
Error	  
0.63µM	   0.97	   0.08	   1.00	   0.04	   1.03	   0.41	  
1.25µM	   0.88	   0.13	   0.86	   0.07	   0.98	   0.45	  
2.5µM	   0.87	   0.03	   0.81	   0.03	   0.93	   0.14	  
5.0µM	   0.82	   0.06	   0.83	   0.02	   1.01	   0.47	  
10.0µM	   0.62	   0.10	   0.64	   0.06	   1.03	   0.47	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Figure	  22	  -­‐	  Average	  of	  the	  normalised	  viability	  of	  MCF10A	  and	  CDH1-­‐/-­‐	  cells	  
after	  treatment	  with	  wortmannin	  (μM).	  Concentrations	  of	  wortmannin	  were	  
0.6µM,	  1.3µM,	  2.5µM,	  5.0µM	  and	  10µM.	  Cells	  were	  treated	  24	  hrs	  after	  seeding.	  
Staining	  and	  counting	  occurred	  at	  48	  hrs	  after	  treatment.	  The	  total	  cell	  count	  of	  6	  
technical	  repeats	  was	  normalised	  to	  the	  average	  of	  the	  DMSO	  control.	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4  DISCUSSION	  
“For	  me,	  I	  am	  driven	  by	  two	  main	  philosophies:	  Know	  more	  today	  about	  the	  world	  
than	  I	  knew	  yesterday	  and	  lessen	  the	  suffering	  of	  others.	  You’d	  be	  surprised	  how	  far	  
that	  gets	  you.”	  –	  Neil	  deGrasse	  Tyson	  
The	  synthetic	  lethal	  response	  between	  CDH1-­‐/-­‐	  cells	  and	  PLK3	  knockdown	  
found	  in	  the	  high	  throughput	  siRNA	  screen	  conducted	  in	  our	  lab	  needed	  
validation	  [27].	  This	  screen	  found	  that	  a	  knockdown	  of	  PLK3	  caused	  a	  
viability	  ratio	  of	  0.84,	  with	  CDH1-­‐/-­‐	  cells	  being	  less	  viable	  than	  their	  isogenic	  
MCF10A	  partner.	  The	  threshold	  to	  be	  considered	  a	  synthetic	  lethal	  
candidate	  was	  to	  have	  a	  viability	  ratio	  less	  than	  0.85.	  PLK3	  also	  had	  
biological	  relevance	  to	  microtubule-­‐associated	  proteins	  that	  were	  
identified	  frequently	  as	  having	  a	  synthetic	  lethal	  affect	  on	  CDH1-­‐/-­‐	  cells.	  
Finding	  a	  synthetic	  lethal	  candidate	  would	  be	  of	  great	  benefit	  to	  the	  
hundreds	  of	  families	  (including	  the	  families	  here	  in	  New	  Zealand)	  that	  
carry	  a	  CDH1	  mutation.	  Currently	  HDGC	  is	  treated	  by	  a	  total	  prophylactic	  
gastrectomy	  to	  remove	  their	  stomach	  and	  remove	  their	  70%	  likelihood	  of	  
developing	  diffuse	  gastric	  cancer.	  Gastrectomy	  has	  a	  100%	  chance	  of	  
surgical	  morbidity,	  and	  can	  have	  serious	  metabolic	  consequences	  leading	  to	  
multiple	  malnutrition	  problems	  [74].	  Hormones	  that	  regulate	  hunger	  
(ghrelin	  and	  leptin)	  that	  are	  produced	  by	  the	  stomachs	  epithelial	  lining	  
become	  deficient.	  Eating	  too	  much	  without	  a	  stomach	  can	  lead	  to	  gastric	  
reflux,	  as	  they	  do	  not	  have	  the	  capacity	  to	  store	  as	  much	  food.	  Vitamin	  B12	  
deficiency	  leading	  to	  megaloblastic	  anaemia	  is	  a	  malnutrition	  risk	  which	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requires	  regular	  supplement	  injections	  [75].	  If	  a	  woman	  has	  HDGC	  she	  is	  
also	  prone	  to	  developing	  lobular	  breast	  cancer.	  In	  addition,	  their	  quality	  of	  
life	  can	  be	  affected	  by	  increased	  antisocial	  behaviour,	  pain,	  fatigue,	  anxiety,	  
and	  reduced	  self	  esteem	  from	  body	  image	  [76].To	  reduce	  the	  burden	  of	  all	  
these	  conditions	  an	  alternative	  preventative	  is	  needed.	  	  
	  A	  perfect	  synthetic	  lethal	  vulnerability	  will	  have	  minimised	  effect	  on	  
normal	  cells	  that	  means	  limited	  toxicity	  to	  the	  patient.	  Ideally,	  only	  the	  cells	  
with	  the	  sporadic	  second	  hit	  and	  inactive	  CDH1	  will	  be	  killed	  by	  the	  
treatment.	  This	  potential	  treatment	  course	  could	  be	  repeated	  at	  regular	  
intervals	  to	  keep	  the	  patient	  free	  of	  advanced	  disease.	  With	  much	  progress	  
in	  identifying	  biologically	  plausible	  targets	  from	  the	  original	  siRNA	  screen,	  
it	  is	  only	  a	  matter	  of	  time	  before	  we	  find	  the	  right	  target	  and	  the	  right	  
compound.	  In	  the	  mean	  time,	  understanding	  genes	  with	  the	  CDH1	  
association	  that	  cause	  synthetic	  lethality	  (such	  as	  the	  microtubule	  
association	  PLK3	  regulated)	  will	  aid	  this	  research	  effort.	  
4.1 PLK3	  KNOCKDOWN	  BY	  SHRNA	  
The	  successful	  knockdown	  of	  PLK3	  from	  the	  transduction	  of	  shRNA	  E4	  
caused	  a	  viability	  ratio	  of	  1.65,	  meaning	  it	  had	  a	  strong	  reverse	  synthetic	  
lethal	  relationship.	  The	  standard	  error	  of	  this	  relationship	  was	  broad	  and	  
the	  p-­‐value	  was	  not	  significant.	  The	  E7	  shRNA	  likewise	  was	  not	  significant	  
and	  did	  not	  show	  a	  synthetic	  lethal	  relationship	  from	  the	  viability	  ratio	  of	  
0.92.	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This	  was	  not	  a	  significant	  relationship	  and	  requires	  further	  biological	  
repeats	  confirming	  a	  PLK3	  knockdown	  to	  answer	  if	  there	  indeed	  were	  a	  
reverse	  synthetic	  lethal	  relationship.	  This	  is	  because	  the	  E7	  shRNA,	  which	  
had	  more	  biological	  repeats,	  did	  not	  cause	  the	  same	  effect	  as	  the	  E4	  shRNA,	  
which	  does	  not	  validating	  the	  specific	  effect.	  Both	  experiments	  confirmed	  a	  
knockdown	  of	  PLK3	  but	  the	  variation	  in	  viability	  was	  substantial.	  
Additional	  knockdown	  repeats	  are	  needed	  but	  it	  is	  most	  likely	  the	  
relationship	  is	  not	  substantial.	  
Error	  in	  the	  expression	  of	  the	  housekeeping	  gene	  PPIA	  in	  the	  RT-­‐qPCR	  
reaction	  may	  have	  been	  influenced	  by	  that	  fact	  that	  multiple	  products	  
appeared	  on	  the	  gel.	  This	  indicates	  the	  PPIA	  primers	  may	  not	  have	  been	  
efficient.	  The	  efficiency	  of	  three	  RT-­‐qPCR	  reactions	  was	  higher	  than	  an	  two,	  
meaning	  a	  doubling.	  A	  reaction	  that	  produces	  more	  than	  double	  each	  cycle	  
is	  not	  possible	  and	  is	  skewed	  by	  errors	  in	  the	  standard.	  These	  results	  were	  
discarded	  as	  unable	  to	  validate.	  Repeating	  RT-­‐qPCR	  a	  second	  time	  for	  each	  
transduction	  was	  not	  achievable	  as	  all	  the	  cDNA	  was	  used	  up	  to	  provide	  
triplicate	  replicates.	  This	  meant	  a	  whole	  new	  transduction	  had	  to	  be	  
carried	  out,	  which	  considering	  the	  growing	  time	  of	  the	  cells	  was	  a	  time	  
consuming	  task	  that	  had	  no	  room	  for	  error	  from	  any	  inadequacies	  or	  
incapability.	  
The	  variability	  in	  the	  shRNA	  synthetic	  lethal	  effect	  can	  be	  caused	  by	  a	  
multitude	  of	  factors.	  The	  original	  siRNA	  screen	  showed	  the	  PLK3	  
knockdown	  was	  only	  synthetic	  lethal	  in	  2/4	  of	  the	  siRNA	  sequences	  (Table	  
2	  and	  Figure	  3).	  The	  siRNA	  sequences	  all	  were	  targeting	  the	  same	  gene,	  but	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there	  is	  potential	  that	  some	  sequences	  are	  a	  better	  match	  and	  are	  more	  
effective	  in	  the	  knockdown	  than	  others.	  Confirming	  the	  knockdown	  was	  
meant	  to	  eliminate	  this	  error,	  but	  the	  variability	  remained.	  	  
Unfortunately	  targeting	  a	  knockdown	  of	  PLK3	  for	  synthetic	  lethality	  was	  
not	  able	  to	  advance	  any	  therapeutic	  leads.	  These	  results	  do	  aid	  in	  future	  
efforts	  to	  validate	  synthetic	  lethality	  in	  other	  potential	  targets;	  the	  viability	  
ratio	  can	  be	  raised	  to	  a	  stricter	  threshold	  based	  on	  this	  validation	  of	  PLK3.	  
The	  original	  screen	  identified	  PLK3	  as	  a	  target	  by	  meeting	  the	  viability	  ratio	  
threshold	  of	  0.85	  but	  it	  eventuated	  to	  be	  non-­‐significant.	  A	  threshold	  of	  
0.75	  would	  have	  greater	  power	  to	  exclude	  the	  noise.	  Results	  of	  the	  PLK3	  
knockdown	  caused	  fluctuations	  in	  the	  cell	  viability	  without	  having	  any	  
consistency.	  This	  is	  also	  reflected	  in	  the	  originally	  individual	  siRNA	  results.	  
The	  screen	  was	  conducted	  at	  a	  high	  throughput	  and	  may	  have	  the	  potential	  
to	  miss	  important	  key	  players,	  which	  only	  was	  an	  outlier	  primarily.	  
Including	  the	  smaller	  synthetic	  lethal	  effects	  at	  a	  0.85	  threshold	  may	  have	  
included	  one	  of	  these	  outliers	  with	  potential	  to	  show	  a	  greater	  synthetic	  
lethal	  effect.	  This	  was	  not	  the	  case	  with	  PLK3.	  
4.2 PLK3	  INHIBITORS	  
4.2.1 POLOXIPAN	  
Poloxipan	  is	  a	  pan	  inhibitor	  of	  the	  polo-­‐like	  kinase	  family	  meaning	  it	  is	  not	  
specific	  to	  PLK3.	  PLK1	  is	  a	  tumour	  promoter	  because	  of	  its	  suppression	  on	  
p53	  that	  is	  being	  researched	  in	  various	  cancers.	  More	  specific	  inhibitors	  of	  
PLK1	  are	  currently	  in	  phase	  I	  and	  II	  trials.	  PLK1	  is	  an	  agonist	  of	  PLK3.	  PLK3	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is	  the	  tumour	  suppressor	  that	  activates	  p53	  causing	  cell	  cycle	  arrest	  and	  
apoptosis.	  Considering	  that	  poloxipan	  inhibited	  both	  of	  these	  Polo-­‐like	  
kinases,	  the	  inconsistency	  and	  non-­‐significant	  effects	  are	  not	  too	  surprising.	  
The	  only	  significant	  relationship	  that	  was	  determined	  was	  the	  reverse	  
synthetic	  lethal	  relationship	  at	  low	  concentrations	  of	  poloxipan.	  Increasing	  
the	  concentration	  of	  poloxipan	  only	  decreased	  the	  viability	  of	  both	  MCF10A	  
and	  CDH1-­‐/-­‐	  cells	  and	  was	  no	  longer	  reverse	  synthetic	  lethal.	  	  
4.3 REVERSE	  SYNTHETIC	  LETHALITY	  
A	  reverse	  synthetic	  lethal	  treatment	  can	  be	  induced	  in	  several	  ways.	  When	  
the	  MCF10A	  cell	  line	  was	  intended	  to	  be	  unaffected,	  treatment	  can	  be	  
reverse	  synthetic	  lethal	  by	  either	  killing	  the	  MCF10A	  cells	  to	  a	  greater	  
extent	  than	  the	  CDH1-­‐/-­‐	  cells.	  The	  other	  way	  a	  treatment	  can	  be	  reverse	  
synthetic	  lethal	  is	  if	  it	  causes	  CDH1-­‐/-­‐	  cells	  to	  proliferate	  and	  grow	  more	  
than	  the	  MCF10A	  and	  control.	  As	  CDH1-­‐/-­‐	  cells	  represent	  the	  HDGC	  tumour	  
cells	  a	  reverse	  synthetic	  lethal	  relationship	  is	  therefore	  one	  that	  would	  
promote	  tumour	  growth	  and	  is	  to	  be	  fully	  avoided	  in	  any	  treatment.	  	  
The	  fact	  that	  this	  trend	  was	  seen	  for	  the	  E4	  shRNA	  is	  potentially	  very	  
problematic	  for	  any	  case	  promoting	  PLK3	  knockdown	  as	  a	  treatment.	  One	  
implication	  returns	  to	  the	  danger	  of	  using	  PLK1	  drug	  inhibitors.	  Current	  
PLK1	  inhibitors	  are	  not	  exclusive	  to	  PLK1	  and	  often	  inhibit	  PLK3	  at	  the	  
same	  concentrations	  at	  which	  they	  target	  PLK1.	  Such	  a	  relationship	  was	  
one	  of	  the	  reasons	  why	  wortmannin	  was	  tested	  in	  this	  experiment	  as	  this	  
PI3K	  inhibitor	  also	  has	  off	  target	  effects	  on	  PLK1	  and	  PLK3	  at	  similar	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concentrations	  at	  which	  it	  would	  be	  inhibiting	  PI3K.	  The	  success	  of	  
wortmannin	  treatment	  for	  cancer,	  inflammation,	  immunology	  and	  
cardiovascular	  disease	  may	  have	  been	  influenced	  by	  the	  polo-­‐like	  kinase	  
inhibition	  [69].	  
4.4 FUTURE	  DIRECTIONS	  
PLK3	  should	  no	  longer	  be	  considered	  a	  strong	  synthetic	  lethal	  candidate	  for	  
E-­‐cadherin	  negative	  cancers.	  However	  the	  results	  were	  not	  consistent	  and	  
further	  validation	  of	  this	  relationship	  can	  be	  done.	  Further	  transductions	  
with	  shRNA	  knockdowns	  are	  needed,	  with	  confirmation	  of	  PLK3	  
knockdown.	  Knocking	  down	  the	  PLK3	  mRNA	  doesn’t	  exclude	  residual	  PLK3	  
proteins	  from	  affecting	  the	  cells.	  Validating	  whether	  the	  knockdown	  led	  to	  
a	  PLK3	  deficient	  cell	  could	  be	  investigated	  by	  a	  western	  blot.	  PLK3	  as	  a	  cell	  
cycle	  regulator	  and	  is	  signalled	  to	  be	  expressed	  every	  cycle.	  It	  can	  be	  
anticipated	  that	  presence	  of	  existing	  PLK3	  will	  decrease	  after	  a	  few	  
completed	  replications.	  
The	  IncuCyte	  images	  showed	  poloxipan	  and	  wortmannin	  treatments	  
caused	  a	  lethal	  effect	  on	  CDH1-­‐/-­‐	  cells	  immediately	  after	  treatment.	  The	  
same	  response	  was	  not	  seen	  to	  the	  same	  degree	  in	  MCF10A	  cells.	  There	  
remains	  potential	  for	  a	  synthetic	  lethal	  effect	  from	  poloxipan	  and	  
wortmannin,	  although	  it	  could	  arguably	  be	  from	  inhibition	  of	  PLK1	  or	  PI3K	  
and	  not	  PLK3.	  Determining	  the	  viability	  at	  48	  hrs	  after	  treatment	  could	  
have	  allowed	  cell	  colonies	  to	  continue	  to	  proliferate	  and	  masked	  any	  true	  
effect	  the	  inhibitors	  do	  produce.	  Conducting	  a	  cell	  luminescence	  assay	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determining	  the	  amount	  of	  viable	  cells	  at	  multiple	  time	  points	  would	  reveal	  
the	  effect	  these	  inhibitors	  have	  on	  viability.	  Multiple	  dosages	  every	  two	  –	  
three	  hrs	  could	  also	  enhance	  any	  potential	  existing	  synthetic	  lethal	  
relationship.	  
The	  clumping	  of	  the	  cells	  in	  response	  to	  PLK3	  inhibition	  was	  also	  of	  
interest	  as	  this	  occurred	  to	  a	  greater	  extent	  in	  the	  CDH1-­‐/-­‐	  cell	  line.	  
Performing	  a	  scratch	  assay	  and	  finding	  the	  migration	  times	  for	  each	  cell	  
line	  in	  response	  to	  the	  treatment	  would	  have	  been	  of	  interest.	  The	  
clumping	  could	  also	  have	  limited	  the	  amount	  of	  drug	  that	  was	  able	  to	  
influence	  the	  cell	  and	  could	  have	  provided	  some	  of	  the	  inconsistencies	  
across	  the	  data.	  The	  clumping	  could	  be	  indicative	  that	  PLK3	  loss	  alters	  cell	  
migration.	  
Attempts	  to	  determine	  if	  the	  effect	  of	  PLK3	  knockdown/inhibition	  was	  
lethal	  compared	  to	  only	  inhibitive	  of	  growth	  were	  not	  consistently	  
recorded.	  Propidium	  iodide	  staining	  served	  as	  an	  indicator	  of	  the	  amount	  
of	  dead	  cells	  and	  was	  available	  for	  two	  of	  the	  successful	  experiments.	  
Repeating	  the	  transduction	  and	  inhibition	  can	  be	  repeated	  to	  derive	  what	  
the	  true	  lethal	  response	  is.	  Cells	  may	  still	  be	  viable	  but	  could	  have	  been	  in	  
cell	  cycle	  arrest.	  The	  plates	  were	  confluent	  so	  cell	  growth	  continued	  to	  
occur,	  as	  they	  were	  not	  seeded	  or	  treated	  at	  confluence.	  Determining	  the	  
stage	  of	  the	  cell	  cycle	  through	  10x	  images	  on	  the	  Cytell	  would	  have	  been	  
beneficial	  to	  observe	  from	  the	  PLK3	  inhibitor	  treatments.	  Including	  further	  
time	  points	  providing	  the	  immediate	  response	  to	  treatment	  would	  also	  
greatly	  assist	  this	  validation.	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4.5 SUMMARY	  
There	  is	  no	  significant	  synthetic	  lethal	  relationship	  between	  CDH1	  and	  
PLK3.	  	  
The	  successful	  knockdown	  of	  PLK3	  using	  lentiviral	  delivery	  of	  shRNA	  
resulted	  in	  a	  reverse	  synthetic	  lethal	  relationship	  from	  the	  E4	  shRNA	  
sequence,	  and	  a	  lethal	  effect	  to	  both	  cell	  lines	  from	  the	  E7	  shRNA	  sequence.	  
The	  p-­‐values	  indicate	  that	  the	  results	  were	  non-­‐significant.	  
Inhibiting	  PLK3	  with	  the	  inhibitors	  poloxipan	  and	  wortmannin	  and	  testing	  
viability	  from	  total	  cell	  count	  48	  hrs	  later	  did	  not	  provide	  a	  synthetic	  lethal	  
relationship.	  Images	  and	  the	  confluence	  measure	  indicated	  that	  CDH1-­‐/-­‐	  
cells	  were	  subject	  to	  a	  greater	  growth	  inhibition.	  This	  information	  remains	  
to	  be	  quantified	  and	  validated	  and	  is	  not	  necessarily	  due	  to	  the	  inhibition	  of	  
PLK3.	  	  
These	  experiments	  indicate	  that	  PLK3	  is	  not	  a	  strong	  synthetic	  lethal	  
candidate	  for	  E-­‐cadherin	  deficient	  cancers.	  As	  PLK3	  was	  representative	  of	  
microtubule	  associated	  regulators,	  this	  provides	  an	  insight	  that	  this	  
association	  may	  not	  be	  the	  vulnerability	  that	  needs	  to	  be	  targeted.	  This	  
validation	  enables	  further	  more	  accurate	  assessments	  of	  the	  remaining	  
synthetic	  lethal	  candidates.	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5  	  APPENDIX	  
5.1 LYSOGENY	  BROTH	  AGAR	  PLATES	  	  
Autoclave	  the	  100mL	  of	  LB	  with	  1.5%	  agar	  (Appendix	  5.2)	  for	  one	  hour.	  
100mL	  of	  LB	  with	  1.5%	  agar	  is	  sufficient	  for	  3	  agar	  plates.	  Once	  cool,	  add	  
200µL	  of	  50mg/mL	  ampicillin	  to	  obtain	  100µg/mL	  and	  swirl	  gently.	  Pour	  
about	  30mL	  of	  the	  agar	  and	  ampicillin	  mix	  into	  a	  94mm	  ×	  16mm,	  vented	  
disposable	  petri	  dish	  (BRAND).	  This	  can	  be	  used	  for	  up	  to	  3	  days	  if	  kept	  in	  
4°C.	  Allow	  to.	  Warm	  at	  room	  temperature	  before	  streaking	  with	  E.coli.	  
5.2 LYSOGENY	  BROTH	  COMPONENTS	  
Combine	  substrates	  in	  a	  1L	  beaker	  and	  mix	  the	  substrates	  together	  using	  a	  
magnetic	  stirrer.	  Pour	  100mL	  into	  a	  200mL	  Schott	  bottle,	  200mL	  into	  a	  
400mL	  Schott	  bottle	  and	  200mL	  into	  a	  second	  400mL	  Schott	  bottle.	  
Table	  11	  -­‐	  Components	  of	  Lysogeny	  Broth	  
Lysogeny	  Broth	  
Component:	   Quantity:	  
Tryptone	   5g	  
Yeast	  Extract	   2.5g	  
NaCl	   10g	  
MQ	  H2O	   500mL	  
Total	   500mL	  ~	  16	  plates	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5.3 RT-­‐qPCR	  PRIMERS	  
Table	   12	   –	   The	   sequences	   of	   the	   RT-­‐qPCR	   reactions	   primers.	   *	   =	   Primers	  
were	  pre-­‐designed	  by	  Integrated	  DNA	  Technologies	  (IDT).	  
Target	   Forward	   Reverse	  
GAPDH*	   GCGCCAATACGACCAA	   GCTCTCTGCTCCTCCTGTT	  
PPIA	  *	   TCTTTCACTTTGCCAAACACC	  	   CATCCTAAAGCATACGGGTCC	  
PLK3	   GCGCGAGAAGATCCTAAATG	   TTGTCAGCGTCCTCAAAGTG	  
	  
5.4 E7	  SHRNA	  KNOCKDOWN	  
	  
Figure	  23	  –	  Average	  of	  the	  viability	  after	  E7	  shRNA	  attempted	  PLK3	  
knockdown	  
	  
	   	  
1.11	   1.06	  
0.88	  
1.02	   1.01	  
1.18	  
1.04	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